Toxicology – Cobalt

Core Concept

Cobalt toxicity depends heavily on the route, dose, chemical form, and duration of exposure. The two major modern clinical patterns are occupational inhalational disease, which can cause occupational asthma and hard-metal lung disease, and chronic systemic cobalt excess, which can produce cardiomyopathy, neurologic and sensory toxicity, thyroid dysfunction, and polycythemia. An important modern source of systemic cobalt toxicity is the release of cobalt from failing cobalt-containing orthopedic implants, particularly mechanically failing or metal-on-metal hip prostheses.

There is no universally accepted blood cobalt concentration that by itself establishes systemic poisoning, and there is no proven specific antidote. Management therefore centers on identifying and removing the source of cobalt exposure, providing supportive care, treating organ-specific complications, and considering chelation only in selected severe cases with medical-toxicology input.

Cobalt and Vitamin B12

Cobalt is present naturally in vitamin B12 (cobalamin), where it forms the central metal atom of the vitamin molecule. Humans therefore require cobalt indirectly through vitamin B12. However, the nutritional requirement is for cobalamin, not for free cobalt ions or inorganic cobalt salts. Cyanocobalamin and other vitamin B12 preparations do not behave toxicologically like soluble cobalt salts because the cobalt atom remains tightly bound within the cobalamin molecule. Routine vitamin B12 use should therefore not be confused with cobalt poisoning.

Forms and Uses

Cobalt is encountered in metallic form, soluble cobalt salts, cobalt oxides, cobalt-containing alloys, pigments, battery materials, catalysts, and medical-device alloys. Important industries include rechargeable battery manufacture and recycling, hard-metal tool production, aerospace superalloys, jet engines, magnets, electroplating, pigments and ceramics, metal refining, welding, diamond-tool manufacture, and chemical processing.

Modern exposure patterns have changed substantially because cobalt is increasingly important in lithium-ion and other rechargeable batteries, making battery manufacture and recycling significant occupational settings.

Hard Metal

“Hard metal” usually consists of tungsten carbide particles held together by cobalt as a binder. Typical formulations contain large amounts of tungsten carbide with smaller percentages of cobalt. Workers involved in manufacturing, grinding, sharpening, polishing, or recycling hard-metal tools can inhale cobalt- and tungsten-containing dust. This exposure is strongly associated with hard-metal lung disease, a distinctive form of occupational interstitial lung disease.

Orthopedic Implant Exposure

A major modern source of systemic cobalt exposure is wear or corrosion from cobalt-chromium orthopedic implants, particularly metal-on-metal hip systems or mechanically failing modular prostheses. Wear and corrosion can release cobalt and chromium particles and ions into surrounding tissues and the circulation.

Systemic cobalt toxicity from an implant should be considered in a patient with a relevant prosthesis who develops unexplained cardiomyopathy, hearing or visual impairment, neurologic changes, thyroid dysfunction, or polycythemia. Assessment must include the implant itself because blood cobalt measurement alone cannot determine whether revision is required.

Radioactive Cobalt

Radioactive cobalt, particularly cobalt-60, is used in industrial radiation sources and radiotherapy. Exposure to radioactive cobalt creates a radiation and internal-contamination problem in addition to ordinary chemical cobalt toxicity. Such exposures require radiation-medicine expertise and should not be managed as simple heavy-metal poisoning.

Toxic Dose

There is no reliable universal toxic dose for cobalt. Older descriptions suggested that airborne concentrations around 20 mg/m³ were potentially lethal and that chronic exposure around 1–2 mg/m³ could cause fatal pulmonary disease. These figures should not be interpreted as direct human lethality thresholds.

The current NIOSH IDLH of 20 mg/m³ is an emergency occupational-exposure benchmark designed to protect workers from conditions immediately dangerous to life or health. It is not an experimentally established human lethal concentration. Toxicity depends on the chemical form of cobalt, particle size, solubility, route, dose, and duration of exposure.

Pathophysiology

Cobalt toxicity is largely related to biologically available Co²⁺ ions. Soluble salts release cobalt ions directly, while poorly soluble particles may be engulfed by cells and subsequently release cobalt intracellularly. Proposed mechanisms include reactive oxygen species formation, oxidative stress, DNA injury, interference with DNA repair, disruption of calcium- and magnesium-dependent processes, and altered mitochondrial and enzymatic function.

One particularly important mechanism is stabilization of hypoxia-inducible factor-1α (HIF-1α). Cobalt can mimic cellular hypoxia and activate hypoxia-response pathways. This contributes to altered erythropoietin signaling and helps explain cobalt-induced polycythemia.

Cardiovascular Toxicity

Severe chronic systemic cobalt exposure may cause cobalt cardiomyopathy. Patients can develop reduced left ventricular function, dilated cardiomyopathy, heart failure, dysrhythmias, and, in extreme cases, cardiogenic shock. Historically, cobalt cardiomyopathy was described in people exposed to cobalt salts added to beer, but contemporary cases are more often associated with excessive cobalt release from orthopedic implants.

Patients with suspected cobalt cardiotoxicity should undergo ECG evaluation and assessment for structural myocardial injury, including echocardiography and, when appropriate, biomarkers such as troponin and BNP or NT-proBNP.

Hematologic Effects

Cobalt can stimulate red-cell production through effects on hypoxia-responsive pathways and erythropoietin signaling. Chronic systemic exposure may therefore produce polycythemia, with increases in hemoglobin, hematocrit, and red-cell count.

An elevated hematocrit in a cobalt-exposed patient should not automatically be attributed to cobalt. Other causes such as chronic hypoxia, smoking, obstructive sleep apnea, and myeloproliferative disease should also be considered.

Thyroid Toxicity

High systemic cobalt exposure can interfere with thyroid function and may produce hypothyroidism or goiter. Symptoms can include fatigue, cold intolerance, weight gain, and other typical manifestations of hypothyroidism. Thyroid dysfunction is an important clue in systemic cobaltism, especially when accompanied by cardiomyopathy or neurologic symptoms, but it is not present in every patient.

Evaluation should include TSH and free T4 when chronic systemic cobalt toxicity is suspected.

Pulmonary Toxicity

The respiratory tract is a major target of occupational cobalt exposure. Inhalation can cause upper-airway irritation, occupational asthma, hypersensitivity-type reactions, and hard-metal interstitial lung disease. Rarely, very high exposures can produce acute pneumonitis or significant hypoxemia.

Workers with chronic exposure may initially complain of nonproductive cough, exertional dyspnea, wheezing, or chest tightness. Persistent symptoms should prompt pulmonary-function testing and high-resolution CT.

Occupational Asthma

Cobalt is a recognized respiratory sensitizer. Sensitized workers may develop cough, wheezing, chest tightness, and reversible airflow obstruction. Once sensitization has occurred, relatively low subsequent exposure may trigger symptoms.

The most important long-term treatment is elimination or substantial reduction of cobalt exposure, because continued workplace exposure can perpetuate airway inflammation even when bronchodilators are effective.

Hard-Metal Lung Disease

Hard-metal lung disease is an occupational interstitial lung disease associated particularly with exposure to cobalt and tungsten carbide. The interaction between cobalt and tungsten carbide appears to enhance oxidative pulmonary toxicity, so the disease should not be viewed as a simple dose-dependent effect of cobalt alone.

Patients often present with progressive dry cough, exertional dyspnea, fatigue, and later hypoxemia. High-resolution CT may show ground-glass opacities, small nodules, reticulation, consolidation, fibrosis, or honeycombing. Pulmonary-function testing may demonstrate restrictive, obstructive, or mixed abnormalities, with reduced diffusion capacity commonly seen.

Giant Cell Interstitial Pneumonia

The classic histopathologic pattern of hard-metal lung disease is giant cell interstitial pneumonia (GIP). Multinucleated giant cells may be found on bronchoalveolar lavage or lung biopsy and are highly characteristic of hard-metal exposure when the occupational history is compatible.

Not every patient with hard-metal lung disease develops the classic GIP pattern. Other histologic appearances can resemble nonspecific interstitial pneumonia, hypersensitivity pneumonitis, usual interstitial pneumonia, or desquamative interstitial pneumonia.

Acute Inhalational Exposure

Acute exposure to high concentrations of cobalt-containing dust or fumes can cause mucous-membrane irritation, cough, dyspnea, bronchospasm, and rarely acute chemical pneumonitis. Patients should be removed immediately from the source and assessed for hypoxemia and respiratory distress.

Supplemental oxygen should be given when indicated, and inhaled β₂-agonists such as albuterol or salbutamol can be used for bronchospasm. Severe respiratory failure may require ventilatory support.

Dermatologic Toxicity

Cobalt is an important contact sensitizer. Dermal exposure may cause irritant dermatitis, allergic contact dermatitis, or a pruritic papular eruption sometimes called “cobalt itch.” Sensitization can become persistent, and later exposure to small quantities of cobalt may provoke recurrent eczema.

Workers exposed to cement, metal dust, pigments, or tools may also be exposed simultaneously to chromium or nickel. Therefore “cement worker’s eczema” should not automatically be attributed only to cobalt. Formal patch testing can help identify clinically important metal allergy.

Gastrointestinal Effects

Acute ingestion of soluble cobalt salts can cause nausea, vomiting, abdominal pain, and diarrhea. Human data describing severe acute gastrointestinal cobalt poisoning are limited compared with the extensive literature on respiratory and chronic systemic toxicity.

The main priorities after significant ingestion are supportive care, assessment for coingestants, and consultation with a poison center or medical toxicologist when the exposure is substantial.

Neurologic and Sensory Toxicity

High systemic cobalt exposure has been associated with neurologic and sensory abnormalities. Patients may experience paresthesias, cognitive changes, fatigue, mood disturbances, peripheral sensory symptoms, and in severe cases hearing impairment and visual or optic-nerve dysfunction.

This combination of auditory and visual abnormalities is particularly important in patients with suspected prosthetic cobaltism. Appropriate assessment may require neurology, audiology, ENT, ophthalmology, or neuro-ophthalmology consultation.

Renal Effects

The kidneys contribute importantly to cobalt elimination, so impaired renal function may reduce clearance and increase systemic cobalt burden. Renal dysfunction has also been reported among patients with systemic metal-ion exposure.

Older descriptions gave substantial emphasis to cobalt-associated glomerulonephritis, but this is not one of the most characteristic modern clinical manifestations of cobalt toxicity.

Carcinogenicity

Modern carcinogenicity classifications differ from older descriptions. Cobalt metal and soluble cobalt(II) salts are classified by IARC as Group 2A, probably carcinogenic to humans. Cobalt(II) oxide is classified as Group 2B, possibly carcinogenic to humans, while some other cobalt compounds remain Group 3, meaning not classifiable regarding carcinogenicity in humans.

It is therefore inaccurate to assign one carcinogenic classification to every cobalt compound. Occupational exposure reduction remains important, particularly for metal and soluble cobalt compounds.

Diagnosis

The diagnosis of cobalt toxicity requires correlation between exposure history, route, cobalt concentration when appropriate, and organ-specific findings. A detailed history should address hard-metal work, tool grinding, welding, battery manufacturing or recycling, pigment production, metal refining, cement exposure, cobalt-containing supplements, and orthopedic implants.

In any patient with otherwise unexplained cardiomyopathy, polycythemia, hypothyroidism, hearing or visual impairment, and a cobalt-containing prosthesis, systemic cobaltism should be considered.

Laboratory Evaluation

For acute significant exposure, testing may include CBC, electrolytes, bicarbonate, glucose, renal function, and liver enzymes according to the clinical picture. Significant respiratory disease may require pulse oximetry, blood gases, and chest imaging.

For chronic or systemic cobaltism, evaluation should include CBC and hematocrit, renal function, electrolytes, TSH and free T4, ECG, and organ-specific testing. Suspected cardiomyopathy may require troponin, BNP or NT-proBNP, echocardiography, and occasionally cardiac MRI.

Patients with neurologic symptoms may need detailed neurologic evaluation, while visual or auditory complaints warrant ophthalmologic and audiologic testing.

Blood Cobalt Measurement

For suspected metal-on-metal or cobalt-containing implant exposure, EDTA-anticoagulated whole blood measured by a validated ICP-MS method is preferred. Specimen type matters, and serum, plasma, and whole-blood cobalt values should not be compared interchangeably.

There is no universally accepted blood cobalt concentration at which systemic toxicity definitely begins. Many severe prosthetic cobaltism cases have involved concentrations above 100 μg/L, but this is not an absolute diagnostic threshold.

Likewise, the widely discussed level of 7 μg/L in implant surveillance is not a universal toxicity threshold. Patients may be asymptomatic above this concentration, while clinically important local implant problems can occur below it. Clinical assessment and implant evaluation remain essential.

Urinary Cobalt

Urinary cobalt can help document recent systemic or occupational exposure and is commonly used in occupational biomonitoring. However, the concentration depends on timing, renal function, and exposure pattern and should not be interpreted as a stand-alone measure of toxicity.

The old statement that “normal urinary cobalt is 0.1–0.2 μg/L” should not be used as a universal modern reference range. Laboratory-specific and occupational reference values should be used instead.

Evaluation of Hard-Metal Lung Disease

Patients with suspected hard-metal lung disease should undergo a detailed occupational history, pulmonary-function testing, and high-resolution CT of the chest. Bronchoscopy with bronchoalveolar lavage or lung biopsy may be required when diagnosis remains uncertain or when giant-cell interstitial pneumonia needs to be confirmed.

Treatment – Remove the Source

The single most important intervention in chronic cobalt toxicity is:

Identify and eliminate the cobalt source.

Workers with suspected cobalt-induced asthma, dermatitis, or lung disease should be removed from continued exposure until proper occupational evaluation is completed.

In prosthetic cobaltism, source control often means evaluation for orthopedic revision or removal of the failing cobalt-containing implant. Chelation alone is unlikely to provide durable benefit if cobalt continues to be released from the prosthesis.

Treatment of Acute Inhalation

After acute inhalation, the patient should be moved to fresh air. Supplemental oxygen is given for hypoxemia, and inhaled β₂-agonists are appropriate for bronchospasm. Severe respiratory failure should be treated with standard ventilatory support.

Systemic corticosteroids may be appropriate when the presentation resembles a significant asthma exacerbation or inflammatory interstitial lung disease, but they are not a cobalt-specific antidote.

Treatment of Hard-Metal Lung Disease

The cornerstone of hard-metal lung disease treatment is complete cessation of exposure. Systemic corticosteroids are commonly used in clinically significant inflammatory disease and may improve symptoms, imaging, and pulmonary function, although evidence is based mainly on observational studies and case series rather than randomized trials.

Advanced fibrotic disease may not fully reverse. Patients with progressive disease require specialist interstitial-lung-disease management, and rare severe cases may eventually require lung transplantation.

Skin and Eye Decontamination

For dermal exposure, contaminated clothing should be removed and the skin washed thoroughly with soap and water. Allergic dermatitis is treated with exposure avoidance and standard dermatologic therapy, often including topical corticosteroids.

Ocular exposure requires immediate copious irrigation with water or saline. Persistent pain, photophobia, corneal injury, or visual change warrants ophthalmologic assessment.

Gastrointestinal Decontamination

Induced vomiting and ipecac should not be used. The historical recommendation for routine ipecac is obsolete.

Activated charcoal is not established as useful for isolated cobalt ingestion because there are no good cobalt-specific human outcome data. Routine gastric lavage is also obsolete and would only be considered under exceptional circumstances involving a very recent, massive, potentially lethal ingestion after airway protection and specialist consultation.

Whole-bowel irrigation may occasionally be discussed after a very large ingestion of radiopaque metallic cobalt or other retained cobalt-containing solid material, but it is not routine therapy.

Antidote and Chelation

There is no established specific antidote for cobalt poisoning. Several chelators have been studied or used in case reports, including CaNa₂EDTA, succimer, DMPS, DTPA, and N-acetylcysteine. However, evidence is sparse and largely case-based.

Chelation should therefore not be started merely because a cobalt concentration is elevated. It is best reserved for selected severe cases after consultation with a medical toxicologist, particularly when the source has already been removed or controlled.

Dimercaprol (BAL) is not standard therapy for cobalt poisoning.

Hemodialysis

Hemodialysis is not an established method for reversing cobalt toxicity in patients with normal renal function. Once cobalt has distributed into tissues, extracorporeal removal may not substantially change clinical outcome.

Dialysis should therefore be used mainly for conventional indications such as severe kidney failure, refractory hyperkalemia, metabolic acidosis, or volume overload rather than solely to remove cobalt.

Cardiomyopathy Management

Cobalt-associated cardiomyopathy should be managed according to standard cardiology and critical-care principles. Treatment may include oxygen when required, diuretics for congestion, guideline-directed heart-failure therapy, vasopressors or inotropes for cardiogenic shock, and mechanical circulatory support in extreme cases.

The crucial toxicologic intervention remains removal of ongoing cobalt exposure, particularly revision of a failing implant when clinically indicated.

Polycythemia and Hypothyroidism

Cobalt-associated polycythemia generally improves after the exposure source is removed. Management should also investigate alternative causes of erythrocytosis.

Patients with clinically significant hypothyroidism should receive standard thyroid replacement therapy when appropriate while the cobalt source is identified and controlled.

Occupational Management

Workers with suspected cobalt-related asthma, dermatitis, or interstitial lung disease should be removed from exposure pending evaluation. Workplace assessment should involve occupational medicine and industrial hygiene, with attention to local exhaust ventilation, engineering controls, respiratory protection, skin protection, workplace monitoring, and process substitution where feasible.

Current Workplace Standards

The current federal OSHA permissible exposure limit for cobalt metal, dust, and fume is 0.1 mg/m³ as an 8-hour TWA. The NIOSH recommended exposure limit is 0.05 mg/m³ as a TWA, and the NIOSH IDLH value is 20 mg/m³.

The 20 mg/m³ IDLH should not be interpreted as a proven lethal concentration. It is a protective emergency-exposure benchmark derived conservatively because robust acute human lethality data are lacking.

Monitoring and Follow-Up

Monitoring should be tailored to the organ systems involved. Respiratory disease requires serial symptoms, PFTs, and imaging when appropriate. Systemic cobaltism may require serial CBC, renal and thyroid function, ECG, echocardiography, neurologic assessment, ophthalmologic testing, audiometry, and repeated whole-blood cobalt concentrations.

Trends in cobalt concentration are generally more informative than a single result, especially after implant revision or other source removal.

Prognosis

Minor acute exposures generally resolve after removal from exposure and supportive care. Allergic contact sensitization may persist indefinitely and recur with very small future exposures.

Occupational asthma may improve after removal from cobalt but can become persistent when diagnosis and exposure cessation are delayed. Hard-metal lung disease has a variable course; inflammatory disease may improve substantially, whereas established pulmonary fibrosis can remain permanent.

Systemic cobaltism may also improve following source removal. Polycythemia and thyroid abnormalities can be reversible, and cardiac function may recover in some patients after implant revision or cessation of exposure. Severe established cardiomyopathy, visual injury, auditory injury, or advanced pulmonary fibrosis may leave permanent deficits.

Important Pitfalls

A major pitfall is assuming that because cobalt occurs in vitamin B12, free cobalt exposure is nutritionally harmless. The body requires cobalamin, not free cobalt ions.

Another important error is thinking cobalt toxicity occurs only in industrial workers. Failing orthopedic implants are now a major clinical source of systemic cobaltism and should be considered when cardiomyopathy, hearing loss, visual impairment, hypothyroidism, cognitive abnormalities, or polycythemia occur in a patient with an appropriate prosthesis.

An elevated blood cobalt concentration does not by itself establish clinical poisoning. There is no universal threshold separating toxic from nontoxic patients, and values such as 7 μg/L or 100 μg/L should not be used as absolute cutoffs.

Serum, plasma, and whole-blood cobalt values are not directly interchangeable. For implant-related assessment, standardized whole-blood testing is preferred.

Chelation is not established routine therapy. Treating a cobalt number without controlling a failing prosthesis or occupational source is unlikely to produce durable improvement.

Hard-metal lung disease should not be described simply as “cobalt pulmonary fibrosis.” The cobalt–tungsten carbide mixture is particularly important, and giant cell interstitial pneumonia is a highly characteristic pathologic clue.

The NIOSH IDLH of 20 mg/m³ should also not be mistaken for a proven lethal concentration. Finally, older recommendations for ipecac, routine gastric lavage, and automatic activated charcoal are obsolete.

High-Yield Toxicology Pearls

Cobalt toxicity should make you think of two main settings: occupational lung disease and systemic cobaltism.

A hard-metal worker with cough and progressive dyspnea should raise concern for cobalt-associated occupational asthma or hard-metal interstitial lung disease. A patient with a cobalt-containing hip prosthesis plus cardiomyopathy, hearing or visual changes, hypothyroidism, neurologic symptoms, or polycythemia should raise concern for prosthetic systemic cobaltism.

The classic hard-metal exposure is tungsten carbide plus cobalt, and the characteristic histologic lesion is giant cell interstitial pneumonia. The first and most important treatment is complete removal from exposure.

Systemic cobalt toxicity can cause cardiomyopathy, polycythemia, hypothyroidism, hearing loss, visual impairment, and neurologic dysfunction. Whole-blood cobalt measured by validated ICP-MS is preferred in implant-related evaluation, but no single cobalt concentration establishes toxicity.

Chelation remains specialist-directed and is not routinely indicated. Hemodialysis is not a reliable cobalt antidote. Acute ingestion should not be treated with ipecac or routine gastric lavage.

Current workplace limits are OSHA 0.1 mg/m³ TWA, NIOSH 0.05 mg/m³ TWA, and NIOSH IDLH 20 mg/m³. The IDLH value is an emergency occupational benchmark, not a human lethal concentration.

The most important principle in chronic cobalt poisoning is:

Find and eliminate the source.

Toxicology – Clonidine

Core concept

Clonidine is a central α₂-adrenergic agonist that produces a characteristic sympatholytic, opioid-like toxidrome in overdose.

The classic syndrome is:

CNS depression + miosis + bradycardia ± hypotension + respiratory depression

A useful sequence is:

Central α₂ stimulation → ↓ sympathetic outflow → sedation + bradycardia + hypotension + hypoventilation

A distinctive additional feature is:

Early transient hypertension → later bradycardia/hypotension

because high clonidine concentrations can initially stimulate peripheral vascular α₂ receptors.

The main treatment is:

Supportive airway/ventilatory care + hemodynamic support

Naloxone is not a specific antidote, but modern pediatric evidence supports a trial—sometimes using substantially higher doses than standard opioid reversal doses—in significant CNS/respiratory depression.

Current Forms

Immediate-release tablets

Current U.S. clonidine hydrochloride tablets are available as:

• 0.1 mg
• 0.2 mg
• 0.3 mg

and remain indicated for hypertension. Current labeling notes commonly used therapeutic doses around 0.2–0.6 mg/day, with 2.4 mg/day described as the maximum effective daily dose, although such high doses are rarely used. (DailyMed⁠)

Extended-release clonidine

Extended-release clonidine is currently used for:

Attention-deficit/hyperactivity disorder (ADHD)

either:

• As monotherapy
• Or with stimulant medication

Current labeling establishes efficacy in children/adolescents:

6–17 years

and uses 0.1-mg extended-release tablets titrated gradually. (DailyMed⁠)

This is an important modernization because pediatric clonidine exposure now commonly occurs from medications prescribed directly to children for ADHD or behavioral disorders rather than solely from a grandparent’s antihypertensive medication. Pediatric poison-center data have shown increasing exposure over time. (PubMed⁠)

Transdermal Clonidine

Current Catapres-TTS systems deliver:

• 0.1 mg/day
• 0.2 mg/day
• 0.3 mg/day

for approximately 7 days. (DailyMed⁠)

Crucial toxicology point

The amount inside the patch is far greater than the nominal daily dose.

Current 2026 Catapres-TTS systems contain approximately:

• 0.1-mg/day patch → 3.09 mg total clonidine
• 0.2-mg/day patch → 6.19 mg
• 0.3-mg/day patch → 9.28 mg

(DailyMed⁠)

Therefore:

A swallowed or chewed clonidine patch is a potentially major overdose.

Even after normal use, a patch can still contain clinically important active drug. Current labeling specifically warns that used patches remain dangerous to infants and children and should be folded adhesive-side-to-adhesive-side and discarded securely. (DailyMed⁠)

Current Uses

Clonidine is currently used for:

• Hypertension
• ADHD
• Selected withdrawal syndromes
• Other specialist/off-label indications

Off-label uses may include:

• Opioid withdrawal
• Tic disorders
• Sleep-related/behavioral indications
• Selected autonomic hyperactivity syndromes

The old chapter’s emphasis on migraine, menopausal flushing, and dysmenorrhea is much less relevant to contemporary exposure patterns.

Toxic Dose

There is:

No single reliable toxic dose.

Children can develop significant toxicity from very small absolute quantities.

Current labeling still notes that:

As little as 0.1 mg has produced toxicity in a child. (DailyMed⁠)

A prospective poison-center study of children <12 years found:

• No coma, respiratory depression, or hypotension among reported ingestions <0.3 mg
• The lowest reported dose producing coma and respiratory depression was 0.3 mg ≈ 15 μg/kg

(PubMed⁠)

A more recent pediatric series found:

• No moderate/severe bradycardia or hypotension below 5 μg/kg
• Some severe hemodynamic effects occurred between 5–10 μg/kg

(PubMed⁠)

Important

These are observational risk ranges—not guaranteed safe cutoffs.

Dose histories after accidental ingestion are often inaccurate.

Thus:

A single 0.1-mg tablet can be clinically important in a small child.

Adults

Adults have survived extremely large overdoses.

Current labeling describes survival after ingestion of:

100 mg

with:

• Initial hypertension
• Subsequent hypotension
• Bradycardia
• Apnea
• Semicoma
• Ventricular ectopy

after intensive supportive treatment. (DailyMed⁠)

Therefore:

Dose alone does not reliably predict mortality.

Pathophysiology

Central α₂-Adrenergic Receptor Agonism

Clonidine stimulates α₂ receptors in the:

• Brainstem
• Medulla

producing:

↓ central sympathetic outflow

which results in:

• ↓ Heart rate
• ↓ Peripheral vascular resistance
• ↓ Blood pressure
• ↓ Sympathetic tone
• Sedation

Current labeling describes clonidine as reducing sympathetic outflow and thereby decreasing peripheral resistance, renal vascular resistance, heart rate, and blood pressure. (DailyMed⁠)

Imidazoline Effects

Clonidine is an imidazoline derivative, and stimulation of central imidazoline receptors probably also contributes to its hypotensive and sedative effects.

This helps explain why structurally related agents such as:

• Tetrahydrozoline
• Naphazoline
• Oxymetazoline

can produce clonidine-like poisoning when ingested.

Why Initial Hypertension Occurs

At high concentrations, clonidine can stimulate peripheral vascular α₂ receptors.

Therefore the early sequence may be:

Peripheral vasoconstriction → transient hypertension

followed by:

Dominant central sympatholysis → bradycardia + hypotension

Current labeling specifically describes:

Early hypertension followed by hypotension and bradycardia. (DailyMed⁠)

Why Naloxone Sometimes Works

The mechanism is uncertain.

Proposed explanations include clonidine-associated:

• Release of endogenous opioids
• Interaction with endogenous endorphin/enkephalin pathways
• Secondary modulation of opioid receptors

This is not established as the principal mechanism of clonidine toxicity.

It nevertheless provides a biologic rationale for the observation that some patients—particularly children—wake dramatically after naloxone. (PubMed Central (PMC)⁠)

Pharmacokinetics

Immediate-release oral clonidine has approximately:

70–80% bioavailability

with peak plasma concentrations generally within:

1–3 hours.

Its elimination half-life is approximately:

12–16 hours

in normal renal function. (DailyMed⁠)

Renal Impairment

Approximately:

40–60% of absorbed clonidine may be recovered unchanged in urine

within 24 hours.

In severe renal impairment, the half-life can increase to approximately:

41 hours

(DailyMed⁠)

Therefore:

Renal impairment can meaningfully prolong clonidine toxicity.

Clinical Features

Classic Toxidrome

The most characteristic findings are:

Sleepy + slow + small pupils

Specifically:

• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia

This can closely resemble opioid poisoning.

Neurologic

Possible manifestations include:

• Drowsiness
• Lethargy
• Somnolence
• Ataxia
• Hypotonia
• Hyporeflexia
• Confusion
• Stupor
• Coma

CNS depression is particularly prominent in children.

Current labeling notes that CNS depression appears more frequently in children than adults. (DailyMed⁠)

Pupils

Miosis is common

and reinforces the similarity to opioid toxicity.

However:

• Miosis is not universal
• Normal pupils do not exclude clonidine
• Pinpoint pupils do not prove an opioid exposure

Respiratory

Clonidine can cause:

• Bradypnea
• Shallow ventilation
• Hypoventilation
• Apnea

Respiratory depression is generally less profound than after a major potent-opioid overdose, but severe pediatric exposures can require mechanical ventilation.

Patients may appear more responsive during physical stimulation and then drift back into hypoventilation when left undisturbed.

Important

Do not rely on repeatedly stimulating the patient as respiratory treatment.

Use objective assessment:

• Respiratory rate
• Capnography when available
• Blood gas when appropriate
• Oxygenation
• Airway reflexes

and ventilate when necessary.

Cardiovascular

Bradycardia

Sinus bradycardia is extremely common.

Adult overdose data found bradycardia in approximately:

76%

with:

• Median onset ~2.5 hours
• Median duration ~20 hours
• Reported duration as long as ~83 hours

(PubMed⁠)

Importantly:

Bradycardia alone is often well tolerated.

Do not treat the monitor simply because the heart rate is low.

Treat if there is:

• Hypotension
• Altered perfusion
• Ischemia
• Syncope
• Shock

Hypotension

Hypotension may result from:

• Central sympatholysis
• Bradycardia
• Reduced vascular resistance

In a large adult overdose series, hypotension occurred in approximately:

24%

and was generally not profound. (PubMed⁠)

Severe shock is possible but uncommon in isolated adult clonidine poisoning.

Initial Hypertension

High-dose exposure may cause early:

Transient hypertension

Current adult data documented early hypertension particularly after large ingestions around 8–12 mg. (PubMed⁠)

It usually precedes the later sympatholytic phase.

Therefore:

Do not reflexively treat early hypertension with a long-acting antihypertensive.

Doing so may worsen the subsequent hypotensive phase.

Conduction Abnormalities

Large overdoses may occasionally produce:

• Sinus-node dysfunction
• Junctional rhythm
• AV block
• Other reversible conduction abnormalities

Serious malignant dysrhythmias are far less characteristic than profound bradycardia.

Hypothermia

Hypothermia may occur because of:

• CNS depression
• Reduced sympathetic activity
• Environmental exposure during prolonged sedation

Use passive/active rewarming according to severity.

Seizures

Seizures are:

Uncommon

and should prompt consideration of:

• Severe poisoning
• Hypoxia
• Coingestion
• Alternative diagnosis

Differential Diagnosis

The most important mimic is:

Opioid poisoning

because both may cause:

• CNS depression
• Miosis
• Respiratory depression

However, clonidine often produces more marked:

Bradycardia

and naloxone response is much less predictable.

Other α₂ / Imidazoline Toxicants

Consider:

• Guanfacine
• Tizanidine
• Dexmedetomidine
• Brimonidine
• Tetrahydrozoline
• Oxymetazoline
• Naphazoline
• Xylazine

Many can produce variations of:

CNS depression + bradycardia + hypotension + miosis

Other Differential Diagnoses

Also consider:

• Benzodiazepines
• Barbiturates
• Baclofen
• Ethanol
• GHB
• Antipsychotics
• β-blockers
• Calcium-channel blockers

and medical causes such as:

• Hypoglycemia
• Hypoxia
• Sepsis
• Hypothyroidism
• Stroke
• Intracranial hemorrhage
• Postictal state

Diagnosis

Diagnosis is primarily:

Clinical

based on:

Exposure history + characteristic sympatholytic/opioid-like syndrome

There is no routinely available bedside clonidine assay required for management.

Clonidine Serum Levels

Serum/plasma clonidine concentrations can be measured by specialized laboratories but are:

• Rarely rapidly available
• Not necessary for routine management
• Poorly suited to emergency decision-making

Therefore:

Treat the patient rather than a clonidine level.

Routine Drug Screens

Standard hospital urine toxicology screens generally:

Do not test specifically for clonidine.

A negative “drug screen” does not exclude clonidine poisoning.

Initial Investigations

Mild known exposure

A completely asymptomatic patient may require little testing beyond clinical observation.

Symptomatic patient

Obtain:

• Bedside glucose
• ECG
• Continuous cardiac monitoring

Consider:

• Electrolytes
• Bicarbonate
• BUN
• Creatinine

particularly with:

• Hypotension
• Significant bradycardia
• Altered consciousness
• Renal disease

Respiratory Assessment

For CNS or respiratory depression consider:

• Continuous pulse oximetry
• Capnography
• Venous/arterial blood gas if significant hypoventilation

Important

A patient receiving oxygen can maintain a normal SpO₂ despite significant CO₂ retention.

Capnography can therefore be more sensitive for evolving hypoventilation.

Intentional Overdose

Also consider:

• Acetaminophen concentration
• Salicylate concentration
• Pregnancy testing when clinically appropriate
• Additional testing guided by coingestants

Treatment

1. Airway and Ventilation

The cornerstone is:

Supportive care

Assess:

• Mental status
• Respiratory rate
• Airway reflexes
• Ventilation

Provide:

• Oxygen if hypoxemic
• Bag-mask ventilation if needed

Intubate for:

• Persistent apnea
• Severe hypoventilation
• Inability to protect airway
• Refractory coma

However, because naloxone can occasionally rapidly reverse clonidine-associated somnolence—particularly in children—a prompt naloxone trial can sometimes avoid unnecessary intubation provided ventilation is being safely maintained while it is given.

Do not delay airway support in a truly unstable patient.

Naloxone

Is Naloxone an Antidote?

Not reliably.

Clonidine’s primary mechanism is α₂ agonism, not opioid-receptor agonism.

Nevertheless:

Naloxone may reverse clonidine-induced CNS depression in some patients.

Current clonidine labeling continues to describe naloxone as a potentially useful adjunct for:

• Respiratory depression
• Hypotension
• Coma

while warning that paradoxical hypertension has occasionally occurred. (DailyMed⁠)

Pediatric High-Dose Naloxone Evidence

Older studies often concluded that naloxone was ineffective, but most used:

≤2 mg

which may be an inadequate trial.

A later pediatric cohort of 52 exposures found:

• 51 were somnolent
• Naloxone awakened 40/51
• Recurrent sedation in some responded to repeat naloxone
• 20 somnolent/bradycardic patients received 10 mg IV naloxone
• 13/20 awoke
• Hypotension resolved in 7/11
• No adverse events occurred even among patients receiving 10 mg

(PubMed⁠)

A 2025 poison-center review therefore recommends considering high-dose naloxone in significant clonidine-induced CNS depression. (Utah Poison Control⁠)

Practical Naloxone Approach

There is no universally validated regimen.

One contemporary poison-center approach uses:

Naloxone 0.1 mg/kg IV, maximum 2 mg per dose

repeated every:

1–2 minutes

with escalation toward a cumulative dose of approximately:

10 mg

if the clinical situation warrants it. (Utah Poison Control⁠)

Some pediatric patients in the published series received a:

10-mg IV bolus

without reported adverse events. (PubMed⁠)

Important

High-dose therapy is best supported in:

Children with significant pure clonidine toxicity who are opioid-naïve.

Consult a poison center/medical toxicologist when escalating to high-dose therapy.

Adults and Naloxone

Evidence is weaker.

In a series of 108 adult clonidine overdoses:

• 23 received naloxone
• Median total dose was only about 2 mg
• Only one had documented partial improvement in consciousness

(PubMed⁠)

This does not prove that higher doses cannot work in adults, but it reinforces that:

Naloxone response is inconsistent.

Do not repeatedly delay definitive airway management waiting for naloxone to work.

Opioid Dependence / Coingestion

If a patient is chronically opioid-dependent or has an opioid coingestion:

High-dose naloxone may precipitate acute withdrawal.

Therefore titrate according to:

• Ventilation
• Clinical context
• Likelihood of opioid dependence

Naloxone Endpoint

The goal is:

Improved ventilation and clinically useful arousal

not necessarily complete wakefulness.

Persistent isolated bradycardia after the patient wakes is common and usually does not require further naloxone merely to normalize the heart rate.

The pediatric naloxone series specifically found patients who became awake despite persistent bradycardia. (PubMed⁠)

Bradycardia

Most clonidine-associated bradycardia is:

Benign if perfusion and blood pressure are adequate.

Do not automatically treat an asymptomatic heart rate of 40–50/min in an otherwise perfusing adult.

Atropine

Use atropine for:

Clinically important bradycardia with hypotension or poor perfusion.

A contemporary adult ACLS regimen is:

Atropine 1 mg IV every 3–5 minutes

to a maximum of:

3 mg

if appropriate.

Pediatric therapy follows current PALS weight-based dosing.

Important limitation

The effect of atropine may be:

• Incomplete
• Transient

Recent pediatric data found only transient improvement in some patients given atropine. (PubMed⁠)

Pacing

Temporary pacing is:

Rarely required

because the bradycardia usually reflects central sympatholysis rather than irreversible conduction-system failure.

Consider pacing only for:

• Severe refractory symptomatic bradycardia
• High-grade AV block
• Persistent hemodynamic instability

after standard supportive therapies have failed.

Hypotension

First-line

Treat with:

Isotonic IV crystalloid

when clinically volume responsive.

Avoid unnecessary large fluid volumes simply because the blood pressure is mildly low.

Vasopressors

For persistent shock despite appropriate fluids:

Vasopressor therapy is appropriate.

There is no strong evidence establishing one uniquely superior agent for clonidine overdose.

A contemporary physiology-based approach is:

• Norepinephrine for persistent vasodilatory hypotension
• Epinephrine may be useful when substantial bradycardia/low cardiac output accompanies shock

The older rule that dopamine is the preferred clonidine vasopressor should not be treated as a modern standard.

Hypertension

Early clonidine-associated hypertension is often:

Transient

and frequently resolves as central sympatholytic effects predominate.

Therefore:

Do not treat an isolated transient elevated blood pressure unless there is severe hypertension with evidence of end-organ injury.

If therapy is genuinely required:

• Use a short-acting
• Titrated IV antihypertensive

under critical-care/toxicology guidance.

Avoid long-acting treatment because profound hypotension may follow.

Seizures

Treat toxin-induced seizures with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

Refractory seizures:

• Phenobarbital
• Propofol in an intubated patient

Also correct:

• Hypoxia
• Hypoglycemia
• Electrolyte abnormalities

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not use ipecac or induced emesis.

CNS depression can develop rapidly.

Current labeling specifically advises against ipecac because of the rapid onset of CNS depression. (DailyMed⁠)

Activated Charcoal

Single-dose activated charcoal may be considered after a:

• Recent
• Potentially significant

tablet ingestion if:

• The patient is fully alert with intact airway reflexes

or:

• The airway has been protected

A typical poisoning dose is approximately:

1 g/kg, usually maximum ~50 g

in routine practice.

Critical point

Do not give charcoal to a progressively somnolent child with an unprotected airway.

The benefit of decontamination is secondary to airway safety.

Gastric Lavage

The current drug label still mentions gastric lavage after recent major ingestion, but modern toxicology practice has moved away from routine lavage.

Therefore:

Routine gastric lavage is not recommended.

It should only rarely be contemplated after an exceptionally large, immediately life-threatening, very recent ingestion with:

• Protected airway
• Appropriate expertise
• Poison-center/toxicology input

Extended-Release Tablets

Because extended-release clonidine is now widely used for ADHD, formulation matters.

Large intentional ER ingestions may:

• Delay absorption
• Prolong the clinical course

A patient with a major ER ingestion warrants longer monitoring than a patient with a reliably tiny immediate-release exposure.

Whole-bowel irrigation is not routine, but could occasionally be considered after a very large modified-release ingestion in an appropriate, stable patient because toxicology position statements allow selected use after potentially toxic sustained-release drug ingestions. (PubMed⁠)

Transdermal Exposure

If toxicity develops while patches are being worn:

Remove every clonidine patch immediately.

Current labeling notes that after patch removal:

• Plasma clonidine persists for approximately 8 hours
• Concentrations then decline slowly over several days

(DailyMed⁠)

Thus:

Removing the patch does not immediately terminate toxicity.

Patch Ingestion

This deserves special attention because the patch reservoir can contain milligram quantities of clonidine.

Current Catapres-TTS patches contain up to:

9.28 mg clonidine

in the largest system. (DailyMed⁠)

A patch that is:

• Chewed
• Sucked
• Swallowed

can therefore produce major toxicity.

Whole-Bowel Irrigation After Patch Ingestion

The current Catapres-TTS label states that:

Whole-bowel irrigation may be considered after patch ingestion. (DailyMed⁠)

However, modern WBI guidance emphasizes that:

WBI should not be performed routinely in poisoned patients.

Evidence that it improves outcomes is limited, and it is contraindicated with:

• Ileus
• Obstruction
• GI perforation
• Hemodynamic instability
• Unprotected airway

(PubMed⁠)

Therefore:

Known clonidine-patch ingestion → early poison-center/medical-toxicology consultation.

WBI is a selective option, not an automatic intervention.

Endoscopic Patch Removal

A 2025 toxicology case report described successful:

Upper-endoscopic removal of an intact clonidine patch from the stomach

approximately 5 hours after ingestion, potentially avoiding prolonged exposure and extended WBI. (Taylor & Francis Online⁠)

This is an emerging case-based strategy, not established routine therapy.

It may be considered when:

• A dangerous intact patch is known to be in the stomach
• Presentation is sufficiently early
• Endoscopy can be performed safely

after multidisciplinary toxicology/GI discussion.

Antidote

There is no proven specific antidote for clonidine poisoning.

Naloxone is best regarded as:

A potentially useful adjunct

rather than a definitive antidote. (DailyMed⁠)

Enhanced Elimination

Hemodialysis

Clonidine is:

Poorly removed by hemodialysis.

Current labeling states that only a minimal amount is removed during routine dialysis and that dialysis is unlikely to significantly enhance elimination. (DailyMed⁠)

Therefore:

Do not dialyze a patient merely to remove clonidine.

Dialysis should be used only for an unrelated conventional indication.

Multiple-Dose Activated Charcoal

There is no established role for:

Multiple-dose activated charcoal

for enhanced clonidine elimination.

Urinary Alkalinization / Forced Diuresis

There is no useful role for:

• Urinary alkalinization
• Forced diuresis

in clonidine poisoning.

Time Course

Immediate-release tablets

Current labeling states that overdose manifestations generally begin within:

30 minutes–2 hours

(DailyMed⁠)

Adult data found median onset of bradycardia somewhat later, approximately:

2.5 hours

with some patients developing it beyond 5 hours. (PubMed⁠)

Duration

Symptoms can be prolonged because clonidine’s elimination half-life is relatively long.

Adult bradycardia lasted a median of approximately:

20 hours

and occasionally persisted much longer. (PubMed⁠)

Severe overdose may therefore produce:

• Sedation
• Bradycardia
• Hypotension

for >24 hours.

Renal impairment can prolong toxicity even further.

Patch Exposure

Patch-related toxicity may have:

• Delayed absorption
• Prolonged absorption
• Prolonged symptoms

and after removal, circulating clonidine can persist for hours followed by a gradual decline over several days. (DailyMed⁠)

Observation

The old universal:

“4–6 hours then discharge”

rule requires nuance.

Immediate-release exposure

For a reliably small immediate-release ingestion, a patient who remains:

• Completely asymptomatic
• Normal mental status
• Normal respiratory status
• Hemodynamically stable
• Normal/reassuring ECG

through approximately 4–6 hours is unlikely to develop major delayed toxicity.

Older pediatric data found no subsequent deterioration more than 4 hours after presentation in children who had remained stable. (PubMed⁠)

Longer Observation Is Appropriate For

• Extended-release clonidine
• Patch ingestion
• Unknown dose
• Large intentional ingestion
• Renal impairment
• Coingestants
• Any symptoms

Therefore:

Disposition should be formulation- and symptom-specific rather than based on a single clock time.

Admission

Hospital admission is appropriate for:

• Persistent CNS depression
• Recurrent naloxone requirement
• Respiratory depression
• Apnea
• Hypotension
• Symptomatic bradycardia
• Significant conduction abnormality
• Large intentional overdose
• Significant ER exposure
• Patch ingestion

ICU

ICU-level care is appropriate for:

• Intubation/mechanical ventilation
• Recurrent apnea
• Severe coma
• Shock requiring vasopressors
• Clinically important conduction disturbance
• Severe coingestant toxicity

Important modernization

Not every patient with:

• Mild isolated bradycardia
• Mild somnolence

requires ICU admission.

Recent pediatric series show that many abnormalities are mild despite being common. (PubMed⁠)

Discharge

Discharge should require:

• Normal/baseline mental status
• Normal ventilation
• Stable blood pressure
• Clinically acceptable heart rate/perfusion
• No recurrent sedation
• No ongoing naloxone requirement
• Adequate observation for the specific formulation

Persistent mild bradycardia may not itself require hospitalization if:

• Patient is asymptomatic
• Perfusion is normal
• Other toxicity has resolved

Intentional overdose requires appropriate psychiatric/safety assessment.

Clonidine Withdrawal

An important issue not emphasized enough in older overdose chapters is:

Abrupt clonidine withdrawal can cause severe rebound sympathetic activity.

Symptoms may include:

• Anxiety
• Agitation
• Tremor
• Headache
• Tachycardia
• Severe rebound hypertension

Rare severe complications include:

• Hypertensive encephalopathy
• Cerebrovascular events
• Death

Current labeling specifically warns against abrupt cessation. (DailyMed⁠)

Why This Matters in Toxicology

After a patient with chronic clonidine use recovers from an overdose, clonidine therapy should not necessarily be withheld indefinitely without a plan.

When clinically safe:

Restart/taper decisions should account for withdrawal risk.

Otherwise the patient can transition from:

Clonidine toxicity → clonidine withdrawal hypertension

Pregnancy

The old FDA Pregnancy Category C system is obsolete.

Current extended-release labeling states that several decades of published human experience have not identified a clonidine-associated increased risk of major congenital malformations, miscarriage, or other major adverse maternal/fetal outcomes. (DailyMed⁠)

In overdose:

Maternal airway, ventilation, perfusion, and blood pressure take priority.

Clonidine crosses the placenta, so significant maternal poisoning may also affect the fetus.

Breastfeeding

Clonidine is present in human milk.

Current extended-release labeling reports a relative infant dose around:

4.1–8.4% of the maternal weight-adjusted dose.

Most reported infants have had no adverse effects, but there is a case report of:

• Sedation
• Hypotonia
• Apnea

in an exposed infant. (DailyMed⁠)

Breastfed infants exposed to maternal clonidine should therefore be monitored for:

• Excess sedation
• Lethargy
• Poor feeding
• Hypotonia
• Respiratory depression
• Bradycardia/hypotension

Prognosis

Most patients recover fully with supportive care.

A large adult series of 108 acute overdoses reported:

• Frequent CNS depression
• Bradycardia in 76%
• Hypotension in 24%
• No deaths
• No significant malignant dysrhythmias

(PubMed⁠)

Serious morbidity is more likely from:

• Respiratory failure
• Prolonged hypoxia
• Large pediatric exposure
• Patch ingestion
• Coingestants

than from the bradycardia itself.

Prevention

Clonidine deserves particular caution in households with children.

Tablets

Store:

• Locked
• Out of sight/reach
• In child-resistant containers

A single 0.1-mg tablet can cause symptoms in a small child. (DailyMed⁠)

Patches

Both:

Used AND unused patches remain dangerous.

Current instructions state that after use, patches should be:

Folded in half with sticky sides together

and discarded carefully out of children’s reach. (DailyMed⁠)

Never assume a “used” patch is pharmacologically empty.

Important Pitfalls

1. Mistaking clonidine poisoning for opioid overdose

Both may produce:

Coma + miosis + respiratory depression

but clonidine typically also produces:

Marked bradycardia

A negative opioid screen does not exclude an opioid, and a positive response to naloxone does not prove an opioid was taken.

2. Using lack of response to 2 mg naloxone to rule out clonidine responsiveness

Older studies often used relatively small naloxone doses.

Pediatric evidence suggests some patients respond only after:

Much larger naloxone exposure, up to approximately 10 mg

(PubMed⁠)

3. Calling naloxone a reliable antidote

Response remains inconsistent.

Supportive care remains definitive treatment.

4. Intubating every sleepy child before considering naloxone

If:

• Ventilation is adequate
• Airway can be safely supported

a prompt naloxone trial—potentially high-dose with poison-center guidance—may occasionally avoid unnecessary intubation. (PubMed⁠)

Do not delay intubation when ventilation is genuinely inadequate.

5. Treating every bradycardic patient

Clonidine-associated bradycardia is often:

Hemodynamically benign.

Treat the:

• Perfusion
• Blood pressure
• Symptoms

not merely the heart-rate number.

6. Assuming atropine will normalize the heart rate permanently

Atropine may provide only:

Transient or incomplete improvement.

(PubMed⁠)

7. Treating transient early hypertension too aggressively

High-dose clonidine can cause:

Hypertension first → hypotension later

Long-acting antihypertensive therapy during the first phase may worsen subsequent shock.

8. Using dopamine automatically

The historical dopamine-first recommendation is outdated.

Use contemporary physiology-driven vasopressor selection.

9. Performing routine gastric lavage

Modern poisoning management does not support routine lavage.

Airway protection and supportive care are much more important.

10. Giving charcoal to a somnolent child

Clonidine can cause rapid CNS depression.

Unprotected airway → no charcoal.

11. Applying the same observation period to IR, ER, and patches

These formulations have different absorption patterns.

Patch and extended-release exposures can require:

Longer observation

than an uncomplicated small immediate-release ingestion.

12. Underestimating patch ingestion

The current largest Catapres-TTS system contains approximately:

9.28 mg clonidine

despite delivering only 0.3 mg/day therapeutically. (DailyMed⁠)

13. Assuming a used patch is safe

It still contains active medication and can poison a child. (DailyMed⁠)

14. Automatically performing whole-bowel irrigation for patch ingestion

WBI may be considered, but:

It is not routine and has no proven outcome benefit.

Use specialist consultation and assess airway/GI contraindications. (PubMed⁠)

15. Forgetting endoscopic retrieval as a possible selected option

A recent case demonstrated successful removal of an intact gastric clonidine patch by upper endoscopy.

This is:

Promising but case-based—not established standard therapy. (Taylor & Francis Online⁠)

16. Dialyzing for toxin removal

Clonidine is poorly cleared by dialysis.

Hemodialysis is not an effective enhanced-elimination strategy.

(DailyMed⁠)

17. Forgetting renal impairment

Severe renal impairment can extend clonidine’s half-life from approximately:

12–16 h → up to ~41 h

(DailyMed⁠)

so prolonged toxicity is more plausible.

18. Forgetting clonidine withdrawal

Abrupt discontinuation after chronic use can cause:

Rebound hypertension + sympathetic hyperactivity

and can itself become dangerous. (DailyMed⁠)

High-Yield Toxicology Pearls

Clonidine = opioid-like toxidrome + bradycardia

Think:

Sleepy + pinpoint pupils + slow pulse

Key points:

• Clonidine is a:
• Central α₂ agonist
• Imidazoline derivative
• Central mechanism:
• ↓ sympathetic outflow
• Classic overdose:
• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia
• Early transient hypertension can occur from peripheral α₂ stimulation
• Current formulations include:
• IR tablets 0.1, 0.2, 0.3 mg
• ER clonidine for ADHD
• Transdermal 0.1, 0.2, 0.3 mg/day
• A single:
• 0.1-mg tablet
• can produce symptoms in a small child
• Recent pediatric data suggest:
• <5 μg/kg carries relatively low risk of major hemodynamic toxicity
• But this is not an absolute safe threshold
• Immediate-release symptoms usually begin:
• 30 min–2 h
• Adult bradycardia:
• Median onset ~2.5 h
• Median duration ~20 h
• Main treatment:
• Supportive care
• Airway/ventilation first
• Naloxone:
• Not a specific antidote
• May reverse clonidine CNS depression
• Pediatric data support high-dose trials in selected cases
• Contemporary poison-center approach:
• ~0.1 mg/kg naloxone, max 2 mg/dose
• Repeat rapidly
• Consider escalation to ~10 mg total/high-dose trial with specialist guidance
• Do not delay intubation for refractory apnea/hypoventilation
• Isolated bradycardia often:
• Does not require treatment
• Symptomatic bradycardia:
• Atropine
• Response may be transient
• Hypotension:
• Fluids if appropriate
• Vasopressor if persistent
• Norepinephrine/epinephrine selected by physiology
• Do not automatically use dopamine
• Early hypertension:
• Usually transient
• Avoid long-acting antihypertensives
• No ipecac
• Routine gastric lavage is obsolete
• Single-dose charcoal:
• Selected early significant ingestion only
• Only with intact/protected airway
• Patch ingestion is especially dangerous:
• Current patches contain 3.09–9.28 mg total clonidine
• Patch ingestion:
• WBI may be considered selectively
• Early endoscopic retrieval is an emerging case-based option
• Dermal patch toxicity:
• Remove every patch
• Levels can persist ~8 h and decline over several days
• Used patches still contain active clonidine
• Hemodialysis:
• Poorly effective for removal
• Severe renal failure:
• Half-life may increase to ~41 h
• Abrupt cessation after chronic therapy:
• Rebound hypertension
• Pregnancy category letters are obsolete
• Current human pregnancy data have not identified a consistent major congenital-malformation signal
• Clonidine enters breast milk; monitor exposed infants for:
• Sedation
• Hypotonia
• Poor feeding
• Apnea
• With adequate airway and cardiovascular support:
• Prognosis is generally excellent

I can continue the next chapter in the same modernized toxicology-reference format.

Toxicology – Ciguatera Fish Poisoning

Core concept

Ciguatera poisoning is a marine neurotoxin syndrome caused primarily by ingestion of seafood containing ciguatoxins (CTXs).

The classic presentation is:

Reef-fish meal → acute gastroenteritis → paresthesias/cold allodynia ± bradycardia/hypotension

The most characteristic neurologic clue is:

Painful or abnormal sensation from cold objects/water

often historically called “hot–cold reversal.”

The major severe complications are:

Profound bradycardia + hypotension + neuromuscular/respiratory weakness

There is:

No proven specific antidote

and modern treatment is principally supportive and symptom-directed. (CDC)

Terminology

“Ciguatera fish poisoning” remains commonly used, but FDA now increasingly uses:

Ciguatera poisoning (CP)

because ciguatoxins can occasionally accumulate in seafood other than finfish, including some:

• Giant clams
• Gastropods
• Lobsters
• Other marine organisms

although fish remain by far the most important human source. (U.S. Food and Drug Administration)

Source of the Toxin

The older description attributing ciguatera simply to:

Gambierdiscus toxicus

is now incomplete.

Ciguatoxins originate from several benthic dinoflagellates belonging mainly to:

• Gambierdiscus
• Fukuyoa

These microorganisms live on:

• Macroalgae
• Turf algae
• Dead coral
• Other reef substrates

Herbivorous fish and invertebrates ingest the dinoflagellates, introducing toxin into the marine food web.

Predatory fish subsequently consume contaminated organisms and accumulate ciguatoxins in their tissues. Modern ecological work demonstrates substantial species-to-species variation in CTX production within Gambierdiscus/Fukuyoa, so the mere presence or abundance of these dinoflagellates does not reliably predict local poisoning risk. (PubMed Central (PMC))

A simplified pathway is:

Gambierdiscus/Fukuyoa → grazing fish/invertebrates → larger reef fish → human ingestion → ciguatera

Ciguatoxin Is the Main Human Toxin

This is an important modernization.

The older chapter attributes human ciguatera to:

• Ciguatoxin
• Maitotoxin
• Scaritoxin

Modern evidence indicates:

Ciguatoxins are the established principal toxins responsible for human ciguatera.

Maitotoxins are produced by some Gambierdiscus species, but:

• They are water-soluble
• Have relatively poor oral absorption
• Do not significantly accumulate through the fish food chain in the same manner
• Have no proven role in ordinary human ciguatera poisoning

Despite their enormous potency when injected experimentally, their relevance to human foodborne ciguatera remains unproven. (PubMed Central (PMC))

“Scaritoxin” is principally of historical interest and should not be presented as a major established clinical toxin alongside CTX.

Ciguatoxins

CTXs are:

• Lipid-soluble
• Polycyclic polyether neurotoxins
• Extremely potent
• Heat stable
• Acid stable

Different geographic families occur, including:

• Pacific CTXs
• Caribbean/Atlantic CTXs
• Indian Ocean CTXs

Their clinical syndromes overlap, although the relative prominence of GI and neurologic findings varies geographically. (PubMed Central (PMC))

Pathophysiology

Voltage-Gated Sodium Channels

The principal molecular effect is:

Persistent activation of voltage-gated sodium channels

CTXs bind to sodium channels and shift their activation toward more negative membrane potentials.

The result is:

Na⁺ influx → neuronal depolarization → spontaneous/repetitive firing → abnormal sensory nerve activity

This produces:

• Paresthesias
• Dysesthesias
• Cold allodynia
• Neuropathic pain
• Autonomic abnormalities

Cellular sodium entry also promotes:

Water influx → neuronal swelling

which historically provided the theoretical rationale for mannitol therapy.

Autonomic Effects

CTXs can disrupt autonomic nervous-system activity.

Clinically this may produce:

• Bradycardia
• Hypotension
• GI hypermotility
• Salivation
• Sweating

A 2024 systematic review of reported ciguatera cardiotoxicity found that among documented cardiac cases:

• Hypotension occurred in approximately 75%
• Bradycardia in approximately 68%
• Sinus bradycardia was the most frequent ECG abnormality
• AV block also occurred

Supportive care generally produced favorable outcomes. (PubMed)

Geographic Distribution

Ciguatera occurs predominantly in tropical and subtropical marine regions, particularly:

• Caribbean
• Gulf of Mexico
• Florida
• Hawaiʻi
• Pacific islands
• Indian Ocean
• Parts of Southeast Asia
• Northern Australia

FDA describes major risk areas approximately between:

35°N and 35°S

although contaminated seafood is now transported globally, so patients can present far from endemic reefs. (U.S. Food and Drug Administration)

Ciguatera distribution also appears to be changing with:

• Ocean warming
• Coral-reef disturbance
• Storms
• Changes in reef ecology
• Global seafood trade

but local risk remains highly variable and difficult to predict. (PubMed Central (PMC))

Fish Associated With Ciguatera

Commonly implicated fish include:

• Barracuda
• Moray eel
• Grouper
• Snapper
• Amberjack
• Jacks/trevally
• King mackerel
• Spanish mackerel
• Sea bass
• Surgeonfish
• Parrotfish
• Wrasse

FDA has also identified ciguatoxins in lionfish from some regions. (U.S. Food and Drug Administration)

Large Predatory Fish

Larger predatory reef fish frequently represent greater risk because of cumulative dietary exposure.

However:

Fish size alone cannot reliably determine whether a fish is toxic.

Modern studies show substantial variability between:

• Species
• Locations
• Individual fish
• Feeding ecology

so the old rule that fish above a particular weight are necessarily toxic is too simplistic. (PubMed Central (PMC))

For prevention, however, CDC still advises travelers to avoid very large reef fish, particularly those:

>5 lb

and especially:

• Barracuda
• Moray eel. (CDC)

The older 3-lb cutoff should therefore not be treated as a scientific toxicity threshold.

High-Risk Fish Parts

CTX concentrations can be particularly high in:

• Liver
• Intestines/viscera
• Head
• Roe

Therefore:

Avoid viscera, head, and roe of reef fish from ciguatera-risk regions.

(CDC)

Cooking Does NOT Protect You

Ciguatoxins are not reliably destroyed by:

• Cooking
• Frying
• Boiling
• Grilling
• Smoking
• Freezing
• Canning
• Pickling
• Salting

The contaminated fish generally:

Looks normal + smells normal + tastes normal.

(CDC)

Therefore:

Proper cooking does not prevent ciguatera.

Toxic Dose

There is no clinically useful human dose threshold.

Illness depends on:

CTX concentration in fish × amount consumed × individual susceptibility

People eating the same fish can develop different illness severity.

A larger serving tends to increase risk, but:

• Small portions can cause significant toxicity
• Not all portions of a contaminated fish have identical toxin concentrations

Onset

Symptoms often begin:

Within approximately 1–6 hours

although onset can be delayed as long as approximately:

30 hours

after eating the implicated seafood. (CDC)

Neurologic manifestations may occasionally appear later, including up to approximately:

96 hours. (CDC)

Geographic Variation in Presentation

CDC notes a useful regional pattern:

Caribbean-type ciguatera

Often:

GI symptoms first → neurologic symptoms later

Pacific-type ciguatera

Neurologic findings may:

• Predominate early
• Occur before GI symptoms
• Occur with relatively modest GI illness

(CDC)

Therefore:

Absence of prominent vomiting/diarrhea does not exclude ciguatera.

Clinical Features

Gastrointestinal

Usually begins with:

• Nausea
• Vomiting
• Abdominal cramping
• Watery diarrhea

GI symptoms usually resolve much sooner than neurologic symptoms.

The diarrhea is ordinarily:

• Nonbloody
• Toxin-mediated

Significant losses can cause:

• Dehydration
• Orthostatic symptoms
• Electrolyte abnormalities

Neurologic – Hallmark Syndrome

Neurologic manifestations include:

• Perioral paresthesia
• Tingling/numbness of hands and feet
• Burning dysesthesia
• Weakness
• Headache
• Dizziness
• Vertigo
• Ataxia
• Fatigue
• Pruritus
• Tremor

Cold Allodynia

The most characteristic symptom is:

Cold allodynia

Cold objects or water can cause:

• Burning
• Electric sensations
• Pain
• Abnormally intense cold sensation

Classical descriptions call this:

“Hot–cold reversal.”

However, modern neurologic studies suggest many patients experience abnormal/painful cold sensation rather than a literal complete reversal in temperature perception.

Therefore:

“Cold allodynia” is the more accurate term.

It is especially noticeable in:

• Hands
• Feet
• Lips
• Oral mucosa

and is highly suggestive of ciguatera when the exposure history fits. (CDC)

Oral/Dental Symptoms

Characteristic but unusual complaints include:

• Metallic taste
• Burning mouth
• Tooth pain
• Sensation that the teeth are loose

These symptoms can be diagnostically useful when combined with:

• Reef-fish exposure
• GI illness
• Paresthesias

(CDC)

Pruritus

Generalized itching can occur:

• Early
• Or after the initial GI illness

It may persist for weeks.

Important correction

The older suggestion that pruritus commonly leads to “cellulitis” is misleading.

Pruritus can produce:

• Excoriations
• Secondary skin injury

but bacterial cellulitis is not a defining feature of ciguatera.

Neuropsychiatric Symptoms

Some patients develop:

• Difficulty concentrating
• Memory impairment
• Sleep disturbance
• Depression
• Anxiety
• Marked fatigue

These may persist after the acute GI syndrome has resolved. (CDC)

Motor / Cranial Nerve Effects

More severe poisoning may cause:

• Generalized weakness
• Cranial-nerve dysfunction
• Ophthalmoplegia
• Dysarthria
• Ataxia
• Rare paralysis

Profound flaccid weakness should also prompt consideration of:

• Paralytic shellfish poisoning
• Tetrodotoxin
• Botulism
• Organophosphate toxicity
• Other neurologic disorders

Cardiovascular

Important manifestations include:

Bradycardia + hypotension

Possible ECG findings include:

• Sinus bradycardia
• AV block
• Ectopy
• Nonspecific repolarization abnormalities

Cardiovascular toxicity is usually most important early in the illness. (PubMed)

Respiratory

Severe cases may produce:

• Dyspnea
• Respiratory depression
• Respiratory-muscle weakness
• Rare respiratory failure

Mechanical ventilation is rarely required but can be lifesaving.

Musculoskeletal

Possible findings include:

• Myalgia
• Arthralgia
• Weakness
• Muscle cramps

CK elevation/rhabdomyolysis is not a defining feature but may occur after:

• Severe weakness
• Prolonged immobility
• Seizures

Severe CNS Effects

Very severe poisoning can occasionally produce:

• Confusion
• Severe encephalopathy
• Seizures
• Coma

but these are uncommon.

If profound CNS depression dominates, evaluate aggressively for:

• Coingestants
• Hypoxia
• Electrolyte abnormalities
• Alternative marine toxins
• Primary neurologic disease

Genitourinary / Sexual Effects

Case reports describe:

• Painful ejaculation
• Pelvic/genital discomfort
• Dyspareunia in the sexual partner

An old case series suggested possible transfer of ciguatoxin through semen, but toxin detection was not definitive.

Therefore:

Sexual transmission remains a case-report observation, not an established common route of poisoning.

(PubMed)

Recurrent / Chronic Symptoms

Neurologic symptoms usually improve over:

Days to weeks

but may persist for:

Months or occasionally longer.

CDC recognizes persistence of neurologic symptoms for months or years in some patients. (CDC)

Possible chronic symptoms include:

• Cold allodynia
• Paresthesias
• Pruritus
• Fatigue
• Weakness
• Headache
• Neuropsychiatric symptoms

Re-Exposure

Repeated ciguatera exposures have sometimes been associated with more severe or recurrent symptoms.

However:

Severity is not predictably greater with every subsequent exposure.

The older statement that repeated episodes are always more severe is too categorical.

Diagnosis

Diagnosis is primarily:

Clinical

based on:

Compatible seafood exposure + characteristic GI/neurologic syndrome

A particularly compelling history is:

Several people who shared the same reef fish develop gastroenteritis + paresthesias/cold allodynia.

No Routine Human Diagnostic Test

There is currently:

No routine clinically available human blood or urine test that confirms ciguatera.

CDC states that diagnosis is based on:

• Symptoms
• Exposure history

rather than a specific human laboratory assay. (CDC)

Fish Testing

If leftover fish is available, specialized laboratories may use methods such as:

• Neuroblastoma cell-based assays
• Receptor-binding assays
• LC-MS/MS

to identify or quantify CTX activity.

These tests are primarily:

• Public-health
• Regulatory
• Research tools

rather than bedside emergency tests. (PubMed Central (PMC))

Practical pearl

If an outbreak is suspected:

Preserve leftover fish rather than discarding it.

It may help confirm the source and protect others.

Laboratory Evaluation

No routine laboratory tests are required in a mild, classic case.

For moderate/severe illness consider:

• Glucose
• Sodium
• Potassium
• Magnesium
• Calcium
• Bicarbonate
• BUN
• Creatinine

These primarily assess:

• Dehydration
• Vomiting/diarrhea
• Alternative diagnoses

ECG / Cardiac Monitoring

Obtain an ECG in patients with:

• Bradycardia
• Hypotension
• Syncope
• Significant weakness
• Severe poisoning

Continuous telemetry is appropriate for clinically significant cardiovascular toxicity.

A 2024 systematic review found sinus bradycardia and AV block among the most common reported ECG abnormalities in ciguatera cardiotoxicity. (PubMed)

CK

Check CK when there is:

• Marked weakness
• Prolonged immobility
• Severe muscle pain
• Seizures

Routine CK measurement in every mild case is unnecessary.

Neuroimaging / Lumbar Puncture

CT/MRI brain or lumbar puncture is not part of routine ciguatera diagnosis.

Use them only when the presentation raises concern for an alternative diagnosis such as:

• Stroke
• CNS infection
• Intracranial hemorrhage
• Encephalitis

Differential Diagnosis

Scombroid poisoning

Usually:

• Very rapid onset
• Flushing
• Headache
• Palpitations
• Urticaria
• Burning/peppery taste

and responds to antihistamines.

Cold allodynia is not typical.

Paralytic Shellfish Poisoning

Caused by saxitoxin.

Features:

• Perioral numbness
• Weakness
• Rapid paralysis
• Respiratory failure

GI manifestations may occur, but cold allodynia is much more characteristic of ciguatera.

Neurotoxic Shellfish Poisoning

Brevetoxin exposure can also cause:

• GI symptoms
• Neurologic symptoms
• Temperature abnormalities

Seafood source and epidemiology help distinguish it from ciguatera.

Tetrodotoxin Poisoning

Usually after:

• Pufferfish
• Certain other marine species

Produces:

• Perioral numbness
• Rapid ascending paralysis
• Respiratory failure

with a generally faster and more paralytic course than ordinary ciguatera.

Botulism

Consider with:

• Cranial neuropathies
• Descending weakness
• Normal sensation

rather than prominent painful paresthesias/cold allodynia.

Organophosphate / Carbamate Poisoning

Look for:

• Salivation
• Lacrimation
• Bronchorrhea
• Miosis
• Fasciculations
• Diarrhea

A cholinergic toxidrome is distinct from classic ciguatera.

Infectious Gastroenteritis

Common bacterial/viral food poisoning can explain:

• Vomiting
• Diarrhea
• Cramping

but does not explain:

Cold allodynia + perioral/extremity paresthesias

Treatment

1. Supportive Care

The core treatment is:

Supportive and symptom-directed care

CDC states that there is no antidote and management is directed toward:

• Hydration
• Cardiovascular stabilization
• Respiratory support
• Symptom relief. (CDC)

2. Fluids and Electrolytes

Vomiting and diarrhea can cause substantial dehydration.

Use:

• Oral rehydration for mild disease
• IV isotonic crystalloid for significant volume depletion

Replace:

• Potassium
• Magnesium
• Other electrolytes

according to measured abnormalities.

3. Antiemetics

For significant nausea/vomiting, use standard antiemetics such as:

• Ondansetron

or another appropriate agent.

There is no ciguatera-specific antiemetic.

4. Diarrhea

Most acute diarrhea is short-lived.

The priority is:

Fluid/electrolyte replacement

rather than aggressively suppressing all bowel activity.

Antidiarrheal treatment may be considered in selected patients once:

• Serious infectious diarrhea is unlikely
• Volume status has been addressed

5. Symptomatic Bradycardia

For clinically important:

Bradycardia + hypotension/poor perfusion

use:

Atropine

according to standard symptomatic-bradycardia practice.

For adults, a contemporary ACLS-style regimen is:

Atropine 1 mg IV

repeated every:

3–5 minutes

to a maximum total of:

3 mg

when clinically appropriate.

The older 0.5-mg starting dose reflects previous resuscitation guidance.

Refractory Bradycardia

If hemodynamically important bradycardia persists despite atropine:

Consider:

• Epinephrine infusion
• Other chronotropic/vasopressor support
• Temporary pacing if truly refractory

in consultation with critical care/toxicology.

Temporary pacing appears to be required rarely; the recent systematic review of 148 reported ciguatera cardiotoxicity cases found no cases requiring temporary or permanent pacing among those reviewed. (PubMed)

6. Hypotension

Treat initially with:

IV isotonic crystalloid

especially because GI fluid losses are common.

CDC specifically notes that orthostatic hypotension generally responds to:

IV fluid + an α-adrenergic agent when necessary. (CDC)

If significant shock persists:

Norepinephrine is a reasonable contemporary vasopressor

with the choice tailored to:

• Bradycardia
• Vasodilation
• Cardiac function

The older routine preference for dopamine and Trendelenburg positioning is outdated.

7. Respiratory Failure

For severe weakness or respiratory depression:

• Oxygen
• Close ventilatory assessment
• Capnography/blood gases when appropriate

Intubate for:

• Respiratory failure
• Severe neuromuscular weakness
• Inability to protect airway
• Coma

8. Seizures

Seizures are uncommon but should be treated with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

For refractory toxin-induced seizures consider:

• Phenobarbital
• Propofol in an intubated patient

Mannitol

Major modernization

The old chapter presents:

IV mannitol as the primary treatment

with a strong claim that early administration improves neurologic outcome.

That claim is not established.

Historical Regimen

The commonly reported regimen is:

Mannitol 1 g/kg IV over approximately 30–60 minutes

usually within:

• 24 hours historically
• Up to 48–72 hours in some contemporary guidance

after symptom onset.

CDC still states that mannitol may be considered during the first 48–72 hours, while acknowledging that evidence is variable. (CDC)

Randomized Trial Evidence

The only double-blind randomized trial compared mannitol with normal saline in 50 patients.

At 24 hours:

• 96% of mannitol patients improved
• 92% of saline patients improved

There was:

No statistically significant clinical advantage from mannitol

and infusion-site discomfort was substantially more frequent with mannitol. (PubMed)

The trial concluded that the findings did not support single-dose mannitol as standard therapy.

Current Role of Mannitol

Therefore:

Mannitol is not a proven first-line antidote.

A reasonable contemporary interpretation is:

• Supportive care and adequate hydration come first
• Routine mannitol is not mandatory
• It may be considered in selected patients with significant acute neurologic symptoms after poison-center/medical-toxicology discussion
• Evidence of benefit remains low quality and conflicting

A later systematic review likewise concluded that the evidence for all pharmacologic ciguatera therapies remains weak. (PubMed)

Mannitol Precautions

Do not give mannitol to a:

• Dehydrated
• Hypotensive
• Hemodynamically unstable

patient before adequate resuscitation.

Potential harms include:

• Osmotic diuresis
• Worsening volume depletion
• Hypotension
• Electrolyte abnormalities
• Renal complications

Thus:

Rehydrate first.

Activated Charcoal

Do not induce vomiting

The old recommendations for ipecac are obsolete.

Do not induce emesis.

By the time ciguatera becomes symptomatic, the toxin-containing food has generally already progressed through the GI tract, and spontaneous vomiting may already be significant.

Gastric Lavage

Routine gastric lavage is not recommended.

There is no evidence that routine lavage improves outcomes, and it can cause:

• Aspiration
• Procedural injury

The old pediatric/adult lavage algorithms should not be used.

Single-Dose Activated Charcoal

CDC Yellow Book states that activated charcoal may be considered when the patient:

• Presents early after ingestion
• Is not vomiting
• Can safely protect the airway

(CDC)

However:

Clinical evidence for improved outcomes is limited.

Therefore it should be viewed as:

Optional early decontamination—not core treatment.

Do not administer it to a:

• Vomiting
• Somnolent
• Unprotected-airway

patient.

Antidote

There is no specific antidote for ciguatoxin poisoning.

(CDC)

Treatment of Persistent Neuropathic Symptoms

Evidence is limited mainly to case reports and case series.

Agents that have been used include:

• Gabapentin
• Pregabalin
• Amitriptyline
• Duloxetine
• Other neuropathic-pain agents

A review found reports of symptom suppression with several of these agents but no high-quality evidence establishing superiority of any particular drug. (PubMed)

Thus:

Treat persistent neuropathic symptoms similarly to other neuropathic pain syndromes, individualized to the patient.

Pruritus

Possible symptomatic treatment includes:

• Antihistamines

although ciguatera-associated itching is neurologic/toxicologic rather than necessarily histamine-mediated, so response may be variable. CDC includes antihistamines among symptomatic therapies. (CDC)

Chronic Fatigue / Mood Symptoms

CDC Yellow Book lists reported symptomatic treatment including:

• Amitriptyline for persistent paresthesias/depression
• Fluoxetine for chronic fatigue

but supporting evidence is limited.

These should not be presented as ciguatoxin-specific antidotes. (CDC)

Hemodialysis / Enhanced Elimination

There is no established role for:

• Hemodialysis
• Hemoperfusion
• Forced diuresis
• Urinary alkalinization

in toxin elimination.

CTX is highly potent, lipid-soluble, and widely distributed into tissues.

Management remains supportive.

Observation

Not every symptomatic patient requires hospital admission.

The older statement:

“Any symptoms → inpatient admission”

is too conservative.

Mild patients with:

• Stable vital signs
• Mild GI symptoms
• Mild paresthesias
• Adequate oral hydration

may often be treated as outpatients after appropriate evaluation.

Admission

Admit patients with:

• Symptomatic bradycardia
• Hypotension
• AV block or significant dysrhythmia
• Severe dehydration
• Significant electrolyte abnormality
• Severe/progressive weakness
• Respiratory symptoms
• Inability to maintain oral hydration
• Altered mental status
• Severe or atypical neurologic toxicity

ICU

ICU-level care is appropriate for:

• Hemodynamic instability requiring vasopressors
• Severe bradycardia/heart block
• Respiratory failure
• Mechanical ventilation
• Severe progressive neuromuscular weakness
• Seizures/coma

Discharge

Discharge is reasonable when:

• Hemodynamics are stable
• Oral hydration is adequate
• No significant bradycardia remains
• No progressive weakness is present
• Respiratory function is normal
• Neurologic symptoms are mild/stable
• Follow-up and return precautions are understood

A patient does not need all paresthesias to disappear before discharge; sensory symptoms may persist for days or weeks.

Prognosis

Most patients recover.

CDC reports a mortality rate:

<0.1%

although risk depends on toxin burden and access to supportive care. (CDC)

GI symptoms usually resolve first.

Neurologic symptoms may persist much longer:

• Days
• Weeks
• Occasionally months or years

Severe respiratory or cardiovascular complications are uncommon with modern supportive care.

Relapse / Triggered Recurrence

Patients sometimes report recurrence or exacerbation of symptoms after:

• Alcohol
• Fish/seafood
• Caffeine
• Nuts

CDC recommends avoiding these trigger foods for up to approximately 6 months after recovery because symptom relapse has been reported. (CDC)

Important nuance

The evidence supporting specific trigger avoidance is largely:

• Observational
• Anecdotal

rather than based on controlled clinical trials.

Therefore:

Do not expand this into the enormous historical list of prohibited substances without evidence.

The older recommendations to avoid:

• Marijuana
• Herbicides
• Insecticides
• Glues
• Epoxies
• Resins
• Cosmetics
• Solvents

for 3–12 months are not supported by robust clinical data.

A pragmatic recommendation is to avoid:

Alcohol and foods personally associated with symptom recurrence, with temporary avoidance of fish, nuts, and caffeine consistent with CDC advice.

Pregnancy

Human pregnancy data remain extremely limited.

Case reports include:

• Normal fetal outcomes after substantial maternal poisoning
• Rare neonatal neurologic abnormalities after maternal poisoning near term

One reported second-trimester severe exposure resulted in a healthy term infant with normal early development. (PubMed)

Therefore:

Ciguatera has not been shown to produce a predictable human teratogenic syndrome.

In a pregnant patient:

• Treat maternal dehydration
• Treat hypotension/bradycardia
• Maintain oxygenation
• Obtain obstetric assessment according to gestational age and maternal severity

Maternal stabilization remains the priority.

Breastfeeding

LactMed currently recommends that:

A mother suspected of having ciguatera poisoning should not breastfeed until she has recovered.

Human data are extremely sparse, but symptoms have historically been suspected in a breastfed infant after maternal ciguatera. (PubMed)

Therefore:

Temporary interruption of breastfeeding during active maternal illness is reasonable.

Public-Health Reporting

Ciguatera frequently occurs in clusters because several people share the same fish.

If poisoning is suspected:

• Ask whether other diners are ill
• Save leftover fish
• Document where the fish was purchased/caught
• Notify appropriate local public-health or food-safety authorities when required

In the United States, FDA specifically encourages healthcare/public-health reporting of seafood toxin illnesses so contaminated products can be investigated and removed from distribution. (U.S. Food and Drug Administration)

Prevention

Because there is no way for a consumer to tell that a fish contains CTX:

Prevention depends on avoiding high-risk seafood rather than preparation technique.

CDC recommends:

• Avoid barracuda and moray eel from ciguatera-endemic areas
• Avoid very large predatory reef fish
• Avoid reef fish >approximately 5 lb where feasible
• Avoid:
• 
  
• Head
• Liver
• Intestines
• Roe
• Remember cooking/freezing does not destroy toxin. (CDC)

Local knowledge and public-health advisories are particularly valuable because toxicity is often highly localized to individual reefs and species.

Important Pitfalls

1. Attributing ciguatera solely to

Gambierdiscus toxicus

Modern taxonomy recognizes multiple toxin-producing:

Gambierdiscus and Fukuyoa species

involved in CTX ecology. (PubMed Central (PMC))

2. Calling maitotoxin an established human ciguatera toxin

Ciguatoxins are the proven major human toxins.

Maitotoxins have no established role in ordinary human ciguatera. (PubMed Central (PMC))

3. Calling temperature reversal mandatory

Some patients literally report hot–cold reversal.

More commonly:

Cold causes abnormal burning/pain — cold allodynia.

The absence of literal reversal does not exclude ciguatera.

4. Waiting for a toxin level

There is:

No routine human ciguatoxin test.

Diagnosis is clinical. (CDC)

5. Forgetting to ask about fish exposure

Patients may present many hours later and may not volunteer a travel or seafood history.

Ask:

• What fish?
• Where caught?
• When eaten?
• Who else ate it?
• Who else is ill?

6. Confusing ciguatera with scombroid

Scombroid classically produces:

Flushing + headache + urticaria/palpitations

whereas ciguatera favors:

Paresthesias + cold allodynia + bradycardia

7. Treating mannitol as a proven antidote

The only blinded randomized trial found:

No benefit over normal saline at 24 hours

and more infusion-related discomfort. (PubMed)

Mannitol remains optional/controversial, not mandatory treatment.

8. Giving mannitol before correcting dehydration

Mannitol causes osmotic diuresis and may worsen:

• Hypovolemia
• Hypotension
• Electrolyte abnormalities

Rehydrate first.

9. Using ipecac

The old ipecac recommendation is obsolete.

Do not induce vomiting.

10. Performing gastric lavage

Routine lavage offers no established benefit and adds aspiration/procedural risk.

11. Automatically admitting every symptomatic patient

Many mild cases can be treated supportively as outpatients.

Admission should be driven by:

• Hemodynamics
• Respiratory function
• Neurologic severity
• Hydration

rather than simply the presence of paresthesias.

12. Using the old 3-lb fish rule

CDC currently advises avoiding reef fish over approximately:

5 lb

as a preventive strategy, but even this is not a guaranteed toxicity cutoff.

Species + location + individual fish matter more than weight alone.

(CDC)

13. Assuming cooking makes the fish safe

CTX survives:

• Cooking
• Freezing
• Smoking
• Canning

(CDC)

14. Eating the liver because the flesh appeared safe

High-risk tissues include:

Liver + viscera + head + roe

and should be avoided in endemic areas. (CDC)

15. Overprescribing long lists of forbidden foods/chemicals

Evidence for chronic symptom triggers is weak.

The best-supported practical advice focuses on:

• Alcohol
• Fish
• Nuts
• Caffeine

rather than the older extensive lists of chemicals and consumer products.

High-Yield Toxicology Pearls

Ciguatera = reef seafood + gastroenteritis + neurologic dysesthesia

Think:

Diarrhea/vomiting → tingling → cold hurts

Key points:

• Principal toxins:
• 
  
• Ciguatoxins
• Source:
• 
  
• Gambierdiscus/Fukuyoa
• Maitotoxin:
• 
  
• Produced by some dinoflagellates
• No proven major role in human ciguatera
• Mechanism:
• 
  
• Persistent activation of voltage-gated sodium channels
• Neuronal depolarization/hyperexcitability
• High-risk fish:
• 
  
• Barracuda
• Moray eel
• Grouper
• Snapper
• Amberjack
• Large reef predators
• High-risk parts:
• 
  
• Liver
• Viscera
• Head
• Roe
• Toxin does not alter:
• 
  
• Taste
• Smell
• Appearance
• Toxin survives:
• 
  
• Cooking
• Freezing
• Canning
• Smoking
• Typical onset:
• 
  
• 1–6 h
• Can be delayed to ~30 h
• Main acute GI symptoms:
• 
  
• Nausea
• Vomiting
• Watery diarrhea
• Abdominal pain
• Hallmark neurologic findings:
• 
  
• Paresthesias
• Cold allodynia
• Perioral numbness
• Metallic taste
• “Loose teeth” sensation
• Severe autonomic findings:
• 
  
• Bradycardia
• Hypotension
• Diagnosis:
• 
  
• Clinical
• No routine human toxin assay
• Save leftover fish for possible specialized testing/public-health investigation
• Treatment:
• 
  
• Supportive care
• IV/oral fluids
• Electrolytes
• Antiemetics
• Symptomatic bradycardia:
• 
  
• Atropine
• Persistent hypotension:
• 
  
• Fluids
• Vasopressor such as norepinephrine when required
• Severe respiratory weakness:
• 
  
• Intubation/ventilation
• No specific antidote
• Mannitol is controversial
• 
  
• Historical dose: 1 g/kg IV
• RCT showed no superiority to saline
• Not routine first-line therapy
• Rehydrate before any consideration of mannitol
• Do not induce vomiting
• No routine gastric lavage
• Activated charcoal:
• 
  
• Optional only after very recent exposure with intact/protected airway and no significant vomiting
• Persistent neuropathic symptoms:
• 
  
• Gabapentin/pregabalin/amitriptyline may be tried
• Evidence is low quality
• Mortality:
• 
  
• <0.1%
• Neurologic symptoms can persist:
• 
  
• Weeks
• Months
• Rarely years
• After recovery, alcohol and several foods can reportedly trigger symptom recurrence
• CDC advises temporary avoidance of:
• 
  
• Alcohol
• Caffeine
• Fish
• Nuts
• Breastfeeding:
• 
  
• Avoid during active maternal ciguatera until recovery
• Prevention:
• 
  
• Avoid barracuda/moray eel
• Avoid high-risk viscera
• CDC advises avoiding very large reef fish, approximately >5 lb
• Suspected clusters should be reported to public-health authorities

Toxicology – Chromium

Core concept

Chromium toxicity depends critically on oxidation state.

The clinically important distinction is:

Hexavalent chromium [Cr(VI)] = highly toxic, corrosive, oxidizing, sensitizing, and carcinogenic

whereas:

Trivalent chromium [Cr(III)] = poorly absorbed and substantially less toxic

The characteristic acute severe syndrome after ingestion of a soluble Cr(VI) compound is:

Caustic gastroenteritis → GI hemorrhage/fluid loss → shock + acute kidney injury + hepatic injury ± coagulopathy/multiorgan failure

Chronic occupational Cr(VI) exposure primarily causes:

Nasal/airway irritation + septal ulceration/perforation + dermatitis/chrome ulcers + occupational asthma + increased lung-cancer risk

The most important modern management principle is:

Treat acute Cr(VI) ingestion as both a severe caustic exposure and a potentially systemic multiorgan poison.

There is no proven specific antidote.

Important Chromium Species

Chromium exists in several oxidation states, but the most relevant are:

Chromium(0)

Metallic chromium.

Used in:

• Stainless steel
• Alloys
• Metal production

It is much less biologically reactive than Cr(VI).

Chromium(III)

Examples include:

• Chromium chloride
• Chromium sulfate
• Chromium oxide

Cr(III):

• Crosses cell membranes poorly
• Is poorly absorbed from the GI tract
• Is much less systemically toxic than Cr(VI)

However:

“Less toxic” does not mean completely harmless.

Specific Cr(III) salts, dusts, or formulations may still cause:

• Local irritation
• Dermatitis
• Occupational exposure problems

The older statement that there is essentially no evidence of Cr(III) toxicity is therefore too broad.

Chromium(VI)

Important Cr(VI) compounds include:

• Chromic acid
• Chromium trioxide
• Potassium chromate
• Potassium dichromate
• Sodium chromate
• Sodium dichromate
• Ammonium dichromate
• Zinc chromate
• Strontium chromate

Cr(VI) is the principal toxicologic concern.

NIOSH lists chromic acid/chromates as capable of causing:

• Respiratory irritation
• Nasal septal perforation
• Kidney/liver injury
• Eye injury
• Skin ulceration
• Sensitization dermatitis
• Lung cancer.

Common Occupational Sources

Exposure occurs particularly during:

• Chrome electroplating
• Stainless-steel welding/cutting
• Chromate pigment manufacture/use
• Stainless-steel and alloy production
• Aerospace painting
• Metal finishing
• Leather tanning
• Wood preservation
• Textile/dye work
• Chromate chemical production
• Work with wet cement containing trace Cr(VI)

NIOSH specifically identifies welding, steel work, electroplating, chromate painting, wood preservation, textile dyeing, and cement work as important Cr(VI) exposure settings.

Why Cr(VI) Is So Much More Toxic

Cr(VI) resembles:

• Sulfate
• Phosphate

anions.

Therefore:

Cr(VI) → enters cells through nonspecific anion transporters

Once intracellular:

Cr(VI) → Cr(V) → Cr(IV) → Cr(III)

during reduction by substances such as:

• Ascorbate
• Glutathione
• Cysteine

This intracellular reduction generates:

• Reactive intermediates
• Reactive oxygen species
• DNA adducts
• DNA-protein cross-links
• Oxidative DNA injury

and contributes to both:

Acute cellular toxicity + carcinogenesis

EPA describes this cellular uptake/reduction mechanism as central to Cr(VI) genotoxicity.

Extracellular Reduction Can Be Protective

An important paradox is:

Cr(VI) reduced to Cr(III) before cellular uptake → generally less toxic

because Cr(III) crosses membranes much less readily.

But:

Cr(VI) reduced after entering the cell → reactive intermediates + cellular damage

This is important when considering proposed vitamin C therapy.

Toxic Dose

There is no sufficiently reliable single dose threshold to guide clinical management.

Historical estimates have placed severe or potentially lethal oral Cr(VI) exposure in approximately the:

50–70 mg/kg range

but major interindividual variation exists, and case reports include both death and survival across a wide range of doses. OSHA has historically cited lethal oral chromate exposures around this range.

Therefore:

Do not use a reported “0.5–1 g lethal dose” as a fixed rule.

Severity depends on:

• Specific Cr(VI) compound
• Concentration
• Solubility
• Dose
• Route
• Delay to treatment
• Degree of caustic GI injury

Acute Ingestion – Clinical Syndrome

Soluble Cr(VI) salts are powerful oxidizing corrosives.

The early syndrome often begins with:

Oral/GI chemical burn → nausea/vomiting → abdominal pain → profuse diarrhea ± GI bleeding

Severe systemic poisoning may then progress to:

Shock → AKI + hepatic injury + coagulopathy → multiorgan failure

Fatal dichromate poisonings have demonstrated rapid progression from gastrointestinal symptoms to hemorrhage, renal/hepatic injury and systemic collapse.

Gastrointestinal Effects

Possible findings include:

• Burning of mouth/throat
• Odynophagia
• Dysphagia
• Severe abdominal pain
• Nausea
• Vomiting
• Diarrhea
• Hematemesis
• Hematochezia
• GI mucosal necrosis

Severe exposures can cause:

• Massive GI hemorrhage
• Perforation
• Peritonitis
• Profound fluid loss
• Hemorrhagic shock

The clinical picture may resemble ingestion of a strong acidic corrosive.

Cardiovascular

Severe Cr(VI) poisoning can produce:

• Tachycardia
• Hypotension
• Circulatory collapse
• Shock

Mechanisms include:

• GI fluid loss
• Hemorrhage
• Capillary/tissue injury
• Metabolic derangement
• Multiorgan toxicity

Renal Toxicity

The kidneys are major systemic target organs.

Possible manifestations include:

• Proteinuria
• Hematuria
• Acute tubular injury
• Oliguria/anuria
• Acute kidney injury

Renal failure is a classic complication of major dichromate poisoning.

Hepatic Toxicity

Severe systemic poisoning may cause:

• Aminotransferase elevation
• Hepatocellular injury
• Acute hepatitis
• Severe hepatic dysfunction

Combined:

AKI + hepatic injury + GI hemorrhage

is particularly suggestive of major systemic dichromate poisoning when exposure history is compatible.

Hematologic Toxicity

Severe poisoning may cause:

• Anemia
• Thrombocytopenia
• Hemolysis
• Coagulopathy
• DIC-like abnormalities

Methemoglobinemia has also been reported in catastrophic dichromate poisoning, but it is not a universal or defining feature.

Neurologic Toxicity

Neurologic effects are usually secondary to severe systemic illness and may include:

• Confusion
• Lethargy
• Encephalopathy
• Coma

Possible contributors include:

• Shock
• Acidosis
• Renal failure
• Hepatic failure
• Hypoxemia

Respiratory Toxicity – Acute Inhalation

Cr(VI) dusts and mists can cause:

• Nasal irritation
• Sore throat
• Cough
• Dyspnea
• Bronchospasm
• Wheezing
• Chemical airway injury

High-level exposures may produce:

• Pulmonary inflammation
• Pulmonary edema

NIOSH recognizes the respiratory tract as a major target organ of chromic acid/chromates.

Occupational Asthma

Cr(VI) can function as a respiratory sensitizer.

Sensitized workers may develop:

• Wheezing
• Chest tightness
• Cough
• Occupational asthma

even after exposures lower than those producing obvious corrosive injury.

OSHA specifically identifies chromium-associated occupational asthma.

Nasal Septal Injury

A classic chronic occupational finding is:

Nasal irritation → ulceration → septal perforation

Symptoms may include:

• Epistaxis
• Nasal irritation
• Crusting
• Ulcers
• Septal perforation

This has historically been particularly associated with:

• Chrome plating
• Chromate production
• Welding

OSHA identifies repeated Cr(VI) exposure as capable of damaging nasal mucosa and causing septal perforation.

“Pneumoconiosis” – Important Correction

The old chapter emphasizes chromium-associated pneumoconiosis.

That is not the most useful modern description of chronic Cr(VI) respiratory disease.

The major recognized occupational pulmonary problems are:

• Chronic upper-airway irritation
• Nasal ulceration/perforation
• Occupational asthma
• Respiratory irritation
• Lung cancer

rather than a characteristic chromium-specific pneumoconiosis.

Skin Toxicity

Chrome ulcers

A classic Cr(VI) lesion is the:

“Chrome hole”

These are often:

• Painless
• Deep
• Punched-out ulcers

and occur particularly on:

• Fingers
• Hands
• Forearms

especially where skin is:

• Cut
• Abraded
• Chronically contaminated

Irritant Dermatitis

Direct exposure can cause:

• Erythema
• Burning
• Irritant contact dermatitis
• Chemical burns

Allergic Contact Dermatitis

Chromium is an important skin sensitizer.

After sensitization:

Very small subsequent exposures can provoke eczema.

OSHA recognizes both irritant and allergic chromium dermatitis, including disease associated with wet Portland cement.

Ocular Exposure

Cr(VI) solutions, dusts, or mists may cause:

• Conjunctivitis
• Severe irritation
• Corneal injury
• Chemical burns

Immediate irrigation is required.

Carcinogenicity

This is one of the most important chronic toxicology points.

Hexavalent chromium compounds are established human carcinogens.

IARC classifies:

• Cr(VI) compounds → Group 1, carcinogenic to humans
• Metallic chromium → Group 3
• Cr(III) compounds → Group 3

with sufficient human evidence particularly for occupationally associated lung cancer.

NIOSH similarly considers Cr(VI) compounds occupational carcinogens and recognizes increased lung-cancer risk in exposed workers.

Cancer Sites

The strongest human evidence is for:

Lung cancer

Occupational data also support concern for:

• Nasal cancer
• Sinonasal cancer

in heavily exposed populations.

Thus, the old statement that chromium “may” cause bronchogenic cancer understates the evidence specifically for Cr(VI).

Diagnosis

Diagnosis depends mainly on:

Exposure history + route + clinical syndrome

Important questions include:

• What chromium compound?
• Cr(VI) or Cr(III)?
• Chromate/dichromate?
• Concentration?
• Ingestion, inhalation, skin, or eye exposure?
• Occupational process?
• Duration/frequency?
• PPE?
• Other metals or chemicals present?

Obtaining the:

• Safety Data Sheet
• Product label
• Workplace exposure information

can be extremely helpful.

Acute Laboratory Evaluation

For significant Cr(VI) ingestion obtain:

• CBC
• Electrolytes
• Bicarbonate
• Glucose
• BUN
• Creatinine
• AST/ALT
• Bilirubin

For severe poisoning also obtain:

• Blood gas
• Lactate
• PT/INR
• aPTT
• Fibrinogen
• LDH
• Haptoglobin
• Reticulocyte count
• Urinalysis
• Type and crossmatch

Consider:

• Methemoglobin concentration

if cyanosis or unexplained hypoxia is present.

ECG

Obtain an ECG in significant systemic poisoning.

Continuous monitoring is appropriate with:

• Shock
• Major electrolyte abnormalities
• Severe acidosis
• Multiorgan failure

Chromium Measurements

Chromium concentrations may document exposure but have important limitations.

Blood / Serum

Chromium clears relatively rapidly from plasma.

Cr(VI) can enter erythrocytes and be reduced to Cr(III), becoming bound intracellularly.

Therefore:

• Serum chromium primarily reflects relatively recent exposure
• RBC chromium can support significant Cr(VI) exposure

ATSDR notes that Cr(VI), unlike Cr(III), enters red cells, so comparing erythrocyte and plasma/serum chromium may sometimes help characterize exposure.

Urinary Chromium

Urinary chromium largely reflects:

Recent absorption over roughly the preceding 1–2 days

and is used more often for occupational biomonitoring than for acute bedside decision-making.

Important

A chromium level is not a clinical severity score.

ATSDR notes that elevated chromium values have not been reliably correlated with specific physiologic effects.

Therefore:

Do not delay resuscitation or caustic-injury evaluation while waiting for chromium measurements.

Hair and Nail Testing

Hair or nail chromium testing is generally:

Not clinically useful

for diagnosing an individual exposure because external contamination cannot be reliably distinguished from incorporated chromium.

Acute GI Injury Assessment

A substantial Cr(VI) ingestion should be managed partly according to modern caustic-ingestion principles.

Consider:

• Gastroenterology
• Surgery
• Medical toxicology/poison center

early.

Endoscopy

For significant symptomatic or intentional Cr(VI) ingestion:

Early upper GI endoscopy is generally considered within approximately 12–24 hours, provided the patient is stable and perforation is not already apparent.

Endoscopy helps determine:

• Esophageal injury
• Gastric injury
• Burn severity
• Future stricture risk

Modern caustic literature generally recommends early endoscopic evaluation when clinically indicated.

CT

Contrast-enhanced CT of the:

• Neck
• Chest
• Abdomen

may be particularly useful in severe poisoning to assess:

• Transmural necrosis
• Perforation
• Mediastinal injury
• Peritoneal injury
• Adjacent structures

CT complements endoscopy rather than being replaced by routine broad CT/MRI scanning of the entire body.

Important Correction to the Old Imaging Advice

The older recommendation:

“CT or MRI from the nose to abdomen in the first few days because abscess develops late”

is not a standard contemporary chromium-poisoning protocol.

Imaging should be:

Targeted to the suspected complication.

Examples:

• CXR/CT chest → severe inhalational injury
• Contrast CT chest/abdomen → suspected deep GI necrosis/perforation
• ENT imaging/endoscopy → severe chronic nasal disease when clinically indicated

Treatment

1. Rescuer / Healthcare Worker Safety

For industrial contamination:

• Wear appropriate gloves
• Eye protection
• Protective clothing
• Respiratory protection if dust/mist remains airborne

Avoid secondary contamination from:

• Contaminated clothing
• Wet solutions
• Chromate dust

2. Airway and Breathing

For significant inhalation or major ingestion:

Assess:

• Airway edema
• Respiratory distress
• Oxygenation
• Ventilation

Provide:

• Oxygen for hypoxemia
• Bronchodilator for bronchospasm

Early intubation is appropriate for:

• Progressive airway edema
• Severe respiratory failure
• Coma
• Inability to manage secretions

3. Circulation

Severe dichromate poisoning may produce profound shock.

Treat with:

• IV isotonic crystalloid when clinically appropriate
• Blood products for major hemorrhage

If shock persists:

Norepinephrine is generally a reasonable contemporary first-line vasopressor.

Correct:

• Acidosis
• Electrolyte abnormalities
• Hypoglycemia

as clinically indicated.

Gastrointestinal Decontamination

Do not induce vomiting

Never induce emesis.

Cr(VI) salts can be intensely corrosive.

Vomiting:

• Re-exposes the esophagus
• Increases aspiration risk
• Can worsen hemorrhage

ATSDR specifically states that vomiting should not be induced because of Cr(VI)’s corrosive effects and risk of rapid clinical deterioration.

Routine Milk/Water Dilution

The older recommendation for routine milk/water dilution should not be carried forward.

Modern caustic-ingestion guidance finds little evidence for benefit, and dilution may produce:

• Vomiting
• Distention
• Aspiration

Thus:

Do not routinely force milk or water after significant Cr(VI) ingestion.

Do Not Neutralize

Do not attempt chemical neutralization with:

• Alkali
• Acid
• Household chemicals

Neutralization can cause an:

Exothermic reaction → additional thermal injury

Activated Charcoal

Routine activated charcoal is not established therapy for Cr(VI) ingestion.

Problems include:

• Caustic injury occurs rapidly
• Aspiration risk
• Vomiting
• Interference with endoscopic visualization
• Uncertain chromium adsorption benefit

Modern caustic guidance advises against routine charcoal for corrosives.

Gastric Lavage

Do not perform routine gastric lavage.

Potential harms include:

• Esophageal re-exposure
• Hemorrhage
• Perforation
• Aspiration

Modern corrosive-ingestion guidance considers lavage contraindicated.

Nasogastric Tubes

Avoid blind NG/OG placement through a severely injured esophagus.

If enteral access is required:

Use endoscopic/surgical guidance when feasible.

Dermal Decontamination

Immediately:

• Remove contaminated clothing
• Remove contaminated jewelry/PPE
• Wash exposed skin thoroughly with soap and water

NIOSH recommends immediate soap flushing after chromic acid/chromate skin contamination.

Do not aggressively scrub damaged skin.

Ascorbic Acid Skin Soaks – Historical Practice

Older toxicology references recommend:

10–20% ascorbic acid skin soaking

after Cr(VI) contamination.

Experimental and historical occupational evidence suggests extracellular reduction of Cr(VI) may reduce local toxicity, and ATSDR discusses older reports of 10% ascorbate reducing chromium dermatitis/ulceration.

However:

This is not a substitute for immediate copious decontamination and is not a routine modern emergency requirement.

Immediate:

• Clothing removal
• Soap/water washing

remains the priority.

Eye Exposure

Immediately:

Irrigate copiously

with:

• Water
• Saline

for at least 15–20 minutes and longer if needed.

Remove contact lenses when possible.

Persistent:

• Pain
• Photophobia
• Corneal injury
• Visual disturbance

requires urgent ophthalmologic evaluation.

NIOSH recommends immediate irrigation after eye exposure.

Ascorbic Acid as an “Antidote”

This is one of the biggest updates to the old chapter.

The theoretical reaction is:

Cr(VI) + reducing agent → Cr(III)

which should reduce membrane penetration if it occurs before cellular uptake.

This is the rationale for vitamin C.

However:

There is no established human clinical evidence supporting a standardized ascorbic-acid antidote regimen for acute Cr(VI) poisoning.

ATSDR specifically states that although extracellular reduction may theoretically protect, human efficacy of ascorbate or other reducing agents has not been established, and intracellular ascorbate can have complex effects on Cr(VI) toxicity.

Therefore the old formula:

“1 g vitamin C per 0.135 g elemental chromium”

should not be used as an established modern antidote protocol.

Practical approach

For a very recent major soluble Cr(VI) exposure:

Discuss any proposed ascorbate therapy with a medical toxicologist/poison center.

It must not delay:

• Resuscitation
• Airway management
• Caustic injury assessment
• Treatment of shock

Dimercaprol (BAL)

The old chapter states:

“Dimercaprol has been used successfully.”

Modern interpretation is different.

BAL is not an established effective antidote for chromium poisoning.

ATSDR states that chelating agents such as:

• Dimercaprol
• EDTA

have not been shown effective in human chromium poisoning.

Therefore:

Routine BAL should not be used.

EDTA and Other Chelators

Similarly:

• CaNa₂EDTA
• Other experimental chelators

do not have an established clinical role.

A toxicokinetic potassium-dichromate case found Ca-EDTA did not meaningfully alter serum, RBC, or urinary chromium kinetics.

Chelation should therefore not be routine therapy.

Hemodialysis

Toxin removal

Chromium rapidly enters cells and binds intracellularly.

Consequently:

Conventional hemodialysis does not reliably remove enough chromium to function as an effective antidotal therapy.

In one detailed case, combined urinary and dialysis elimination represented only about:

0.16% of the ingested chromium dose

despite prompt dialysis.

Other severe cases similarly found little clinically meaningful chromium removal by:

• Hemodialysis
• Hemoperfusion
• Exchange transfusion.

When Dialysis IS Appropriate

Hemodialysis remains appropriate for conventional renal indications such as:

• Refractory metabolic acidosis
• Severe hyperkalemia
• Volume overload
• Uremic complications
• Severe AKI

Thus:

Dialysis treats the renal/metabolic consequences—not reliably the chromium body burden.

ATSDR likewise states that hemodialysis has not been shown effective as a specific chromium-removal treatment.

Hemoperfusion / Exchange Transfusion

These are not routine therapies.

Historical reports failed to demonstrate reliable clinical benefit or meaningful removal of the largely intracellular chromium burden.

GI Hemorrhage

Treat severe bleeding with:

• Large-bore IV access
• Type/crossmatch
• Packed RBCs
• Appropriate plasma/platelets when indicated

Early:

• Gastroenterology
• Surgery

involvement is appropriate.

Perforation / Transmural Necrosis

Suspect perforation with:

• Severe worsening abdominal/chest pain
• Peritoneal signs
• Pneumomediastinum
• Free intraperitoneal air
• Sepsis
• Shock
• Rising lactate/acidosis

This requires:

Immediate surgical evaluation.

Nutrition

Significant Grade IIb/III caustic injury may require:

• Temporarily restricted oral intake
• Carefully planned enteral feeding
• Postpyloric feeding
• Occasionally parenteral nutrition

The old automatic recommendation for parenteral nutrition after severe injury is overly broad.

Modern practice favors:

Enteral nutrition whenever it can be delivered safely.

Antibiotics

Routine prophylactic antibiotics are not indicated merely because chromium was ingested.

Use antibiotics for:

• Perforation
• Mediastinitis
• Peritonitis
• Aspiration pneumonia
• Documented infection

Corticosteroids

There is no established role for corticosteroids to treat systemic chromium poisoning.

For caustic esophageal injury, routine systemic steroids are also not reliably proven to prevent strictures.

Their use should therefore not be automatic.

Inhalational Exposure – Treatment

Remove from exposure.

Provide:

• Fresh air
• Oxygen if hypoxemic
• Inhaled β₂ agonist for bronchospasm

Severe respiratory injury may require:

• Noninvasive support in selected cases
• Intubation
• Lung-protective ventilation

For sensitization/occupational asthma:

Removal from continued chromium exposure is critical.

Chronic Dermatitis / Chrome Ulcers

Management includes:

• Eliminate ongoing exposure
• Local wound care
• Treat secondary infection only when present
• Occupational-health evaluation

Allergic dermatitis may require:

• Topical anti-inflammatory therapy
• Dermatology/occupational medicine assessment
• Avoidance of further chromium exposure

Repeated exposure after sensitization may provoke dermatitis at very low concentrations.

Nasal Disease

Workers with:

• Recurrent epistaxis
• Nasal ulceration
• Persistent crusting
• Septal damage

need:

• Removal/reduction of exposure
• Occupational medicine evaluation
• ENT assessment when clinically indicated

The old recommendation to wash the nose daily and routinely apply zinc/barium ointment is not a modern standard treatment strategy.

Exposure control is far more important.

Occupational Cancer Prevention

Because Cr(VI) is a carcinogen:

Engineering controls and exposure prevention are the central long-term intervention.

Important measures include:

• Local exhaust ventilation
• Process enclosure
• Substitution when feasible
• Appropriate respiratory protection
• Skin protection
• Hygiene facilities
• Exposure monitoring
• Occupational medical surveillance

Current Workplace Standards – Cr(VI)

The workplace limits in the old chapter are substantially outdated.

OSHA

Current federal OSHA Cr(VI) standard:

PEL = 5 μg/m³ as an 8-hour TWA

and:

Action level = 2.5 μg/m³ as an 8-hour TWA

This equals:

0.005 mg/m³

not the old 0.25 mg/m³ value.

NIOSH

Current NIOSH recommended exposure limit:

0.2 μg/m³ = 0.0002 mg/m³ as Cr(VI), 8-hour TWA

NIOSH treats Cr(VI) as an occupational carcinogen.

This is 25-fold lower than the OSHA PEL.

ACGIH

Current OSHA chemical-data listings cite an ACGIH value of:

0.0002 mg/m³ inhalable particulate TWA

with:

0.0005 mg/m³ STEL

for Cr(VI).

NIOSH IDLH

For chromic acid/chromates:

IDLH = 15 mg/m³ as Cr(VI)

Do Not Apply Cr(VI) Limits to All Chromium

Occupational limits differ by oxidation state.

For example, NIOSH lists much higher limits for:

• Chromium metal
• Cr(II)
• Cr(III)

reflecting their markedly different toxicology.

Therefore:

Always specify the chromium species when discussing occupational exposure.

Occupational Biomonitoring

Urinary chromium can help assess recent occupational uptake.

However:

• It varies between individuals
• It reflects mainly recent exposure
• It does not directly predict disease
• It may normalize despite a clinically important past exposure

ATSDR emphasizes these limitations and notes that urinary chromium primarily represents absorption within the previous 1–2 days.

Occupational monitoring is best interpreted with:

• Air measurements
• Job/task assessment
• PPE evaluation
• Clinical findings

rather than in isolation.

Admission

ICU admission

ICU-level management is appropriate after significant Cr(VI) ingestion with:

• Severe GI burns
• GI hemorrhage
• Hypotension/shock
• Severe metabolic acidosis
• AKI
• Hepatic injury
• Coagulopathy
• Altered mental status
• Respiratory failure
• Multiorgan dysfunction

Hospital Admission

Admission is generally appropriate for:

• Any clearly significant soluble Cr(VI) ingestion
• Persistent vomiting/diarrhea
• Dysphagia/odynophagia
• Abdominal or chest pain
• Hematemesis
• Renal abnormalities
• Hepatic abnormalities
• Significant inhalational injury

A deliberate Cr(VI) ingestion should not be discharged merely because initial vital signs are normal.

Disposition After Minor Exposure

A truly trivial exposure to:

• Metallic chromium
• Low-risk Cr(III) material

may require only decontamination and assessment.

However:

Known ingestion of soluble Cr(VI) deserves a low threshold for prolonged medical evaluation

because systemic renal/hepatic injury can evolve after the initial corrosive symptoms.

Prognosis

Minor local exposure

Usually favorable after adequate decontamination.

Chronic occupational exposure

Can result in:

• Persistent sensitization
• Chronic dermatitis
• Nasal septal damage
• Occupational asthma
• Increased cancer risk

Severe Cr(VI) ingestion

Can produce:

• Massive GI hemorrhage
• AKI
• Hepatic failure
• Coagulopathy
• Shock
• Multiorgan failure
• Death

Case reports demonstrate that deterioration may be rapid despite aggressive therapy.

Long-Term GI Follow-Up

Patients with significant caustic esophageal injury are at risk for:

• Esophageal stricture
• Dysphagia
• Gastric outlet obstruction

Grade IIb/III caustic injuries require gastroenterology follow-up.

Later progressive dysphagia warrants:

• Contrast evaluation
• Endoscopy

as appropriate.

Pregnancy

There is no chromium-specific antidotal therapy that should supersede maternal resuscitation.

After severe exposure:

Maternal airway, oxygenation, circulation, renal function, and caustic injury management are priorities.

Occupational Cr(VI) exposure during pregnancy should be minimized according to exposure-control standards.

Important Pitfalls

1. Treating all chromium as equally toxic

This is the fundamental error.

Cr(VI) ≫ Cr(III) in toxicologic importance.

2. Calling Cr(VI) merely a “heavy-metal poisoning”

Acute soluble Cr(VI) ingestion is also:

A severe corrosive ingestion

with potentially catastrophic local GI injury.

3. Using the old fixed lethal dose

The old:

0.5–1 g = lethal

rule is unreliable.

Risk depends on compound, dose, concentration, and clinical findings.

4. Missing systemic toxicity after the initial GI burn

After vomiting/abdominal pain, monitor for:

AKI + hepatic injury + coagulopathy + shock

5. Calling chromium pneumoconiosis the dominant chronic lung disease

The major chronic Cr(VI) respiratory hazards are:

• Nasal injury
• Asthma
• Respiratory irritation
• Lung cancer

6. Underestimating cancer risk

Cr(VI) compounds are IARC Group 1 human carcinogens.

7. Assuming Cr(III) and metallic chromium have the same carcinogenic classification

IARC classification:

• Cr(VI) → Group 1
• Cr(III) → Group 3
• Metallic chromium → Group 3

8. Inducing vomiting

Cr(VI) salts are corrosive.

Do not induce emesis.

ATSDR specifically advises against it.

9. Routinely diluting with milk/water

Modern caustic management does not support forced dilution because clinical benefit is unproven.

10. Giving activated charcoal routinely

Chromium-associated caustic injury is not a standard charcoal indication.

Airway safety and endoscopic visualization matter more.

11. Performing gastric lavage

Routine lavage is contraindicated.

It can provoke:

• Hemorrhage
• Re-exposure
• Aspiration
• Perforation

12. Treating vitamin C as a proven antidote

Reduction of extracellular Cr(VI) to Cr(III) is mechanistically attractive.

But:

Human efficacy and dosing are not established.

13. Using the old fixed vitamin-C formula

The historical:

1 g vitamin C per 0.135 g chromium

regimen is not an evidence-based modern standard.

14. Routinely giving BAL

Dimercaprol has not been shown effective in human chromium poisoning.

15. Assuming EDTA works because chromium is a metal

CaNa₂EDTA does not have an established therapeutic role.

Chromium toxicity should not be managed by automatically applying lead-poisoning chelation protocols.

16. Using dialysis as a chromium antidote

Chromium rapidly becomes intracellular.

Hemodialysis may remove only a tiny fraction of a major dose.

Use dialysis for:

AKI/metabolic indications

rather than expecting reliable toxin clearance.

17. Relying on chromium blood/urine levels to grade severity

They can confirm recent exposure but correlate poorly with clinical effects.

Treat the patient, not the chromium number.

18. Using hair chromium analysis

Hair/nail testing is easily confounded by external contamination and is generally not clinically useful for individual diagnosis.

19. Using the old occupational PEL

Old chapter:

~0.25 mg/m³

Modern OSHA Cr(VI) PEL:

0.005 mg/m³ = 5 μg/m³

High-Yield Toxicology Pearls

Chromium toxicology = always ask which valence state

Think:

Cr(VI) = corrosive + systemic poison + occupational carcinogen

Key points:

• Important forms:
• Chromium metal
• Cr(III)
• Cr(VI)
• Cr(VI) is much more toxic than Cr(III)
• Important Cr(VI) compounds:
• Chromic acid
• Chromium trioxide
• Potassium dichromate
• Sodium dichromate
• Chromates
• Mechanism:
• Cr(VI) resembles sulfate/phosphate
• Enters cells via anion transporters
• Intracellular reduction → Cr(V)/Cr(IV)/Cr(III) + ROS
• DNA/protein injury
• Acute ingestion:
• Caustic GI burns
• Vomiting/diarrhea
• GI hemorrhage
• Shock
• AKI
• Hepatic injury
• Coagulopathy
• Multiorgan failure
• Skin:
• Chrome holes
• Irritant dermatitis
• Allergic contact dermatitis
• Respiratory:
• Nasal irritation
• Septal ulceration/perforation
• Occupational asthma
• Cancer:
• Cr(VI) = IARC Group 1
• Strong association with lung cancer
• Cr(III) and metallic chromium:
• IARC Group 3
• Diagnosis is primarily:
• Exposure history
• Clinical syndrome
• Blood/urine chromium:
• Can document recent exposure
• Do not reliably grade toxicity
• Urinary chromium mainly reflects exposure over the previous 1–2 days
• Significant Cr(VI) ingestion → evaluate as caustic ingestion
• Endoscopy generally within ~12–24 h when indicated
• Contrast CT helps evaluate deep/transmural injury
• Do not induce vomiting
• Do not neutralize
• Routine milk/water dilution is not recommended
• Routine activated charcoal is not established
• Gastric lavage is contraindicated/not routine
• Skin:
• Remove clothing
• Immediate soap-and-water decontamination
• Eyes:
• Immediate copious irrigation
• No proven antidote
• Vitamin C:
• Mechanistically reduces Cr(VI) → Cr(III)
• Human therapeutic benefit is unproven
• Old fixed-dose protocol should not be used routinely
• BAL:
• Not recommended routinely
• EDTA:
• No established role
• Hemodialysis:
• Poor chromium removal after intracellular uptake
• Use for standard AKI/metabolic indications
• Modern occupational Cr(VI) limits:
• OSHA PEL: 5 μg/m³ 8-h TWA
• OSHA action level: 2.5 μg/m³
• NIOSH REL: 0.2 μg/m³ 8-h TWA
• NIOSH IDLH: 15 mg/m³ as Cr(VI)
• Prevention and occupational exposure control are central because chronic Cr(VI) exposure is carcinogenic

Toxicology – Cholinergic Agonist Medications

Core concept

Direct cholinergic agonists produce toxicity by stimulating acetylcholine receptors directly rather than by inhibiting acetylcholinesterase.

The characteristic syndrome is predominantly:

Muscarinic receptor stimulation → salivation + lacrimation + diaphoresis + vomiting/diarrhea + miosis + bradycardia + bronchospasm/bronchorrhea

The most important severe manifestations are:

Bronchospasm/bronchial secretions + bradycardia/hypotension → respiratory and cardiovascular compromise

The principal antidote is:

Atropine

A crucial distinction from organophosphate poisoning is:

Pralidoxime has no mechanistic role in an isolated direct cholinergic agonist overdose

because acetylcholinesterase has not been inhibited.

Classification

Cholinergic drugs are divided into:

1. Direct-acting cholinergic agonists

These drugs bind directly to cholinergic receptors.

Important examples include:

Choline esters

• Acetylcholine
• Bethanechol
• Carbachol
• Methacholine

Alkaloid/direct muscarinic agonists

• Pilocarpine
• Cevimeline
• Muscarine
• Arecoline

Current reviews classify acetylcholine, methacholine, carbachol, bethanechol, pilocarpine, muscarine, and cevimeline as direct-acting parasympathomimetics.

2. Indirect cholinergic agonists

These increase acetylcholine by inhibiting acetylcholinesterase.

Examples include:

• Neostigmine
• Pyridostigmine
• Physostigmine
• Donepezil
• Rivastigmine
• Organophosphates
• Carbamate insecticides
• Nerve agents

These are different toxicologic entities, particularly because oximes such as pralidoxime act on inhibited AChE and therefore apply principally to selected anticholinesterase poisonings, not direct receptor agonists.

Important Current Agents

Acetylcholine

Current U.S. MIOCHOL-E contains acetylcholine chloride for:

Intraocular use to produce rapid miosis during ophthalmic surgery.

Acetylcholine is rapidly hydrolyzed by cholinesterases, so systemic toxicity from correct intraocular use is unusual.

It activates both:

• Muscarinic receptors
• Nicotinic receptors

but has an extremely short duration.

Bethanechol

Bethanechol is primarily a:

Muscarinic receptor agonist

It is relatively resistant to acetylcholinesterase and has little clinically important nicotinic action.

Current oral dosing remains approximately:

10–50 mg three or four times daily

for selected urinary-retention indications.

Typical adverse/toxic effects include:

• Salivation
• Sweating
• Flushing
• Abdominal cramping
• Diarrhea
• Urinary urgency
• Miosis
• Bronchoconstriction
• Hypotension

Current labeling explicitly identifies atropine as the antidote for bethanechol overdose.

Carbachol

Carbachol is distinctive because it has:

Both muscarinic and nicotinic cholinergic agonist activity

Current MIOSTAT 0.01% is used intraocularly to:

• Produce miosis during surgery
• Reduce early postoperative intraocular-pressure elevation after cataract surgery.

2026 update

A new ophthalmic combination:

YUVEZZI — carbachol 2.75% + brimonidine 0.1%

received U.S. approval in 2026 for treatment of:

Presbyopia in adults.

Therefore the older view of carbachol solely as an intraoperative/glaucoma medication is incomplete.

Methacholine

Methacholine is primarily a:

Muscarinic agonist

and the old description grouping methacholine with strongly nicotinic drugs is misleading.

Current PROVOCHOLINE is used for:

Methacholine bronchial-challenge testing

to diagnose airway hyperresponsiveness in adults and children ≥5 years without clinically apparent asthma.

It is deliberately administered to provoke:

M3 receptor activation → bronchial smooth-muscle contraction → bronchoconstriction

Current labeling carries a boxed warning for:

Severe bronchoconstriction

even at low doses.

It is contraindicated when baseline:

• FEV₁ <60% predicted
• or
• Adult FEV₁ <1.5 L.

Severe methacholine-induced bronchospasm should be reversed promptly with a:

Rapid-acting inhaled β₂ agonist

such as albuterol/salbutamol.

Pilocarpine

Pilocarpine is predominantly a:

Direct muscarinic agonist

Current systemic oral pilocarpine is indicated for:

• Xerostomia following radiotherapy for head/neck cancer
• Xerostomia associated with Sjögren syndrome.

Ophthalmic pilocarpine remains used in selected ophthalmologic settings.

Systemic effects can include:

• Profuse sweating
• Salivation
• Nausea
• Diarrhea
• Urinary frequency
• Bradycardia
• Hypotension
• Bronchospasm

Current labeling notes historical fatal overdoses at doses presumed to exceed approximately:

100 mg

and regards 100 mg as potentially fatal, although this should not be interpreted as a precise clinical threshold.

Cevimeline

Cevimeline should be added to the modern list.

It is a direct muscarinic agonist currently used for:

Dry mouth in Sjögren syndrome.

It can cause:

• Sweating
• Salivation
• Nausea
• Bronchoconstriction
• Bradycardia/hemodynamic changes

Current labeling warns that it may:

• Increase airway resistance
• Increase bronchial smooth-muscle tone
• Increase bronchial secretions

and it is contraindicated in uncontrolled asthma.

Natural Cholinergic Agonists

The older source mixes several natural products together; these require correction.

Pilocarpus

Pilocarpus plants contain pilocarpine, not arecoline.

Areca Nut

The seed of:

Areca catechu

contains:

Arecoline

Arecoline is predominantly a muscarinic partial agonist but also has activity at selected nicotinic acetylcholine receptors.

Acute areca-nut exposure can produce:

• Salivation
• Sweating
• GI hyperactivity
• Tachycardia or bradycardia
• Tremor
• CNS stimulation

Important terminology correction

“Betel quid” commonly contains:

• Areca nut
• Betel leaf
• Lime
• Sometimes tobacco

The principal source of arecoline is the areca nut, not the Piper betle leaf itself.

Muscarine-Containing Mushrooms

Muscarinic mushroom poisoning is classically associated with:

• Inocybe
• Clitocybe

species.

The older inclusion of Boletus as a principal muscarine-containing genus is not appropriate for the classic muscarinic mushroom syndrome.

Symptoms usually begin rapidly—often within:

30 minutes to 2 hours

and include:

• Salivation
• Lacrimation
• Diaphoresis
• Miosis
• Vomiting/diarrhea
• Bronchospasm
• Bradycardia/hypotension

Atropine produces rapid improvement when muscarinic symptoms are clinically significant.

Pathophysiology

Muscarinic receptors

Five muscarinic receptor subtypes exist:

M1–M5

The most clinically important toxic effects involve:

M2 — heart

Activation causes:

• Reduced SA-node firing
• Reduced AV conduction
• Bradycardia

M3 — glands/smooth muscle

Activation causes:

• Salivation
• Lacrimation
• Sweating
• Bronchoconstriction
• Bronchial secretion
• GI hypermotility
• Bladder contraction
• Miosis

Thus:

M3 activation → wet patient

while:

M2 activation → slow heart

Nicotinic Receptors

Nicotinic receptor stimulation may cause:

• Ganglionic autonomic activation
• Tachycardia
• Hypertension
• Skeletal-muscle fasciculations
• Weakness

However:

Pronounced nicotinic neuromuscular toxicity is much more characteristic of anticholinesterase poisoning than of most therapeutic direct muscarinic agonists.

Carbachol has meaningful nicotinic activity.

Arecoline also has some nicotinic activity.

By contrast:

• Bethanechol → predominantly muscarinic
• Methacholine → predominantly muscarinic
• Pilocarpine → predominantly muscarinic

Therefore the old chapter overstates expected nicotinic toxicity from methacholine.

Clinical Syndrome

A useful mnemonic remains:

DUMBELS

• D — Diarrhea / diaphoresis
• U — Urination
• M — Miosis
• B — Bradycardia / bronchospasm / bronchorrhea
• E — Emesis
• L — Lacrimation
• S — Salivation

Another practical approach is:

Wet + wheezy + slow

HEENT

Possible findings:

• Miosis
• Blurred vision
• Lacrimation
• Salivation
• Rhinorrhea

Ophthalmic exposure may produce:

• Ciliary spasm
• Brow ache/headache
• Miosis
• Blurred vision
• Reduced night vision

Dermatologic

Muscarinic stimulation of eccrine sweat glands causes:

Profuse diaphoresis

The patient may therefore be:

• Wet
• Cool
• Clammy

rather than dry as in an anticholinergic toxidrome.

Cardiovascular

Possible findings include:

• Bradycardia
• Hypotension
• AV block
• Reduced cardiac output

Low-dose vasodilatory effects may sometimes produce:

Hypotension → reflex tachycardia

so tachycardia does not absolutely exclude a muscarinic drug exposure.

Pilocarpine and cevimeline labeling both warn that cholinergic effects may alter heart rate and hemodynamics, particularly in patients with underlying cardiovascular disease.

Respiratory

The most immediately dangerous manifestations are:

Bronchospasm + increased bronchial secretions

Patients may develop:

• Cough
• Wheezing
• Chest tightness
• Dyspnea
• Hypoxemia

Patients with:

• Asthma
• COPD
• Other obstructive lung disease

are at higher risk.

Pilocarpine can increase airway resistance, bronchial tone, and secretions.

Methacholine is deliberately bronchoconstrictive and can cause severe bronchospasm even during properly conducted diagnostic testing.

Gastrointestinal

Typical findings:

• Nausea
• Vomiting
• Abdominal cramping
• Borborygmi
• Diarrhea

Severe vomiting/diarrhea can produce:

• Volume depletion
• Electrolyte abnormalities

Genitourinary

Muscarinic stimulation can cause:

• Urinary urgency
• Increased bladder contraction
• Incontinence

Bethanechol’s therapeutic effect itself depends on increasing detrusor activity.

Neurologic

Most direct peripheral muscarinic agonists produce less dramatic CNS toxicity than organophosphate poisoning.

Possible manifestations include:

• Headache
• Dizziness
• Tremor
• Confusion

Seizures and coma are uncommon in isolated routine direct-agonist overdose and should prompt consideration of:

• Massive exposure
• Hypoxia
• Coingestant
• Alternative diagnosis
• Anticholinesterase poisoning

The older chapter likely overstates seizure/coma as routine manifestations of this medication class.

Neuromuscular Findings

Significant:

• Fasciculations
• Generalized weakness
• Flaccid paralysis

should raise suspicion for:

Organophosphate/carbamate anticholinesterase poisoning

rather than a straightforward bethanechol or pilocarpine overdose.

Carbachol and arecoline can have some nicotinic effects, but profound neuromuscular paralysis is not the usual syndrome of therapeutic direct muscarinic agonists.

Toxic Dose

There is no useful class-wide statement that:

“Two or three times the daily dose is toxic.”

The agents vary greatly in:

• Potency
• Route
• Absorption
• Duration
• Receptor selectivity

For example:

• Methacholine is inhaled in tightly controlled diagnostic doses
• Acetylcholine is predominantly intraocular
• Pilocarpine is orally systemically active
• Carbachol is commonly ophthalmic/intraocular
• Bethanechol is oral
• Cevimeline is oral

Therefore:

Risk assessment must be agent-specific.

Diagnosis

Diagnosis is primarily clinical:

Known direct cholinergic exposure + predominantly muscarinic toxidrome

Look for:

Salivation + diaphoresis + GI hyperactivity + miosis + bronchospasm ± bradycardia

Cholinesterase Levels

This is an important distinction from pesticide poisoning.

RBC acetylcholinesterase and plasma butyrylcholinesterase levels are not useful for direct cholinergic agonist poisoning.

These drugs stimulate receptors directly.

They do not require inhibition of acetylcholinesterase.

Therefore:

Normal cholinesterase activity is expected and does not argue against direct muscarinic-agonist toxicity.

Laboratory Testing

Mild toxicity

No routine laboratory testing may be necessary.

Moderate/severe toxicity

Consider:

• Glucose
• Electrolytes
• Bicarbonate
• BUN
• Creatinine

For significant vomiting/diarrhea:

• Potassium
• Magnesium

For severe respiratory illness:

• Blood gas
• Lactate

For repeated seizures/prolonged immobilization:

• CK

ECG

Obtain an ECG and cardiac monitoring for:

• Bradycardia
• Syncope
• Hypotension
• Significant systemic overdose
• Cardiovascular symptoms

Possible abnormalities include:

• Sinus bradycardia
• AV block
• Reflex tachycardia

Respiratory Assessment

Patients with:

• Wheezing
• Dyspnea
• Bronchospasm

should have:

• Pulse oximetry
• Serial lung examination

Peak flow/spirometry may be helpful in selected cooperative patients.

Chest radiography is not routine but may be appropriate with:

• Persistent hypoxemia
• Aspiration
• Suspected pulmonary edema
• Alternative pulmonary diagnosis

Differential Diagnosis

Most important toxicologic differential

Organophosphate poisoning

Produces:

• Muscarinic excess
• Nicotinic weakness/fasciculations
• CNS effects

and typically causes cholinesterase inhibition.

Carbamate insecticides

Also inhibit acetylcholinesterase, usually reversibly.

Therapeutic AChE inhibitors

Examples:

• Donepezil
• Rivastigmine
• Galantamine
• Neostigmine
• Pyridostigmine

Muscarinic mushrooms

Especially:

• Inocybe
• Clitocybe

Nicotine

May produce a mixed:

• Cholinergic
• Adrenergic
• Neuromuscular

syndrome.

Treatment

1. Airway and breathing

Assess immediately:

• Ability to handle secretions
• Bronchospasm
• Work of breathing
• Oxygenation
• Ventilation

Provide:

• Suction
• Oxygen when indicated
• Assisted ventilation if necessary

Intubate for:

• Severe respiratory failure
• Inability to protect airway
• Refractory bronchospasm with fatigue
• Severe CNS depression

2. Atropine

Atropine is the specific pharmacologic antagonist for dangerous muscarinic toxicity.

It competitively blocks muscarinic receptors.

Atropine improves:

• Bronchial secretions
• Bronchospasm
• Salivation
• Bradycardia
• Muscarinic hypotension
• GI hyperactivity

It does not directly reverse nicotinic skeletal-muscle weakness.

Current references specifically recommend parenteral atropine for overdose of direct parasympathomimetic drugs.

Atropine Dosing

Direct muscarinic-agonist poisonings often require much less atropine than severe organophosphate poisoning.

Current product labeling provides examples:

Pilocarpine overdose

Atropine 0.5–1 mg IV or SC, titrated to clinical response.

Bethanechol overdose

Current labeling recommends approximately:

0.6 mg atropine in adults

with repeat dosing according to response.

In severe poisoning

When clinically important:

• Bronchorrhea
• Bronchospasm
• Bradycardia
• Hypotension

persist, IV atropine should be repeated and titrated clinically rather than limited by an arbitrary maximum dose.

Atropine Endpoint

Treat the dangerous physiology rather than the pupils.

The most useful endpoints are:

Adequate ventilation + controlled bronchial secretions + improvement in bronchospasm + adequate perfusion

Do not continue atropine simply to produce:

• Complete mouth dryness
• Mydriasis
• A particular heart rate

Avoid Over-Atropinization

Because most direct agonist overdoses are shorter and milder than organophosphate poisoning, excessive atropine can easily produce an anticholinergic toxidrome:

• Tachycardia
• Dry flushed skin
• Hyperthermia
• Urinary retention
• Ileus
• Agitation
• Delirium

Thus:

Use enough atropine to control dangerous muscarinic effects—not automatically massive organophosphate-style doses in every patient.

Pralidoxime (2-PAM)

Pralidoxime is NOT indicated for an isolated direct cholinergic agonist overdose.

Mechanism:

Pralidoxime → reactivates inhibited acetylcholinesterase

But with:

• Bethanechol
• Pilocarpine
• Methacholine
• Carbachol
• Cevimeline

there may be no inhibited enzyme to reactivate.

Therefore:

Direct agonist → atropine

not:

Direct agonist → atropine + pralidoxime

When Pralidoxime May Still Be Appropriate

If the exposure is unclear and the patient could instead have:

• Organophosphate poisoning
• Mixed pesticide exposure
• Nerve-agent exposure

then manage according to the suspected anticholinesterase syndrome, which may include pralidoxime.

Methacholine-Specific Bronchospasm

If severe bronchoconstriction follows methacholine challenge:

Give a rapid-acting inhaled β₂ agonist immediately

such as:

• Albuterol
• Salbutamol

This is specifically required by current Provocholine labeling.

Atropine may be appropriate if there are broader systemic muscarinic manifestations, but inhaled β₂ agonist treatment is central to reversing methacholine-provoked bronchoconstriction.

Bronchospasm From Other Muscarinic Agonists

Treat with:

• Atropine
• Inhaled β₂ agonist as an adjunct

Oxygen and ventilatory support are added according to severity.

Do not rely on albuterol alone if marked:

• Secretions
• Bradycardia
• Generalized cholinergic toxicity

are present.

Hypotension

First assess whether hypotension reflects:

• Muscarinic bradycardia
• Vasodilation
• Volume depletion from vomiting/diarrhea

Initial therapy

• Atropine when bradycardia/cholinergic excess is contributing
• Isotonic crystalloid if volume responsive

If persistent shock remains:

Norepinephrine is generally an appropriate contemporary vasopressor.

The historical use of Trendelenburg positioning as therapy is obsolete.

Seizures

Although uncommon with isolated therapeutic direct agonists, toxin-induced seizures should be treated with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

For refractory seizures:

• Phenobarbital
• Propofol in an intubated patient

Also correct:

• Hypoxia
• Hypoglycemia
• Electrolyte abnormalities

Gastrointestinal Decontamination

Do not induce vomiting

No ipecac or induced emesis.

Spontaneous vomiting and respiratory secretions increase aspiration risk.

Activated Charcoal

Activated charcoal is not routinely necessary for every direct cholinergic drug exposure.

A single dose may be considered after a:

• Recent
• Clinically significant
• Oral ingestion

if:

• The airway is intact/protected
• Vomiting is not severe
• Aspiration risk is acceptable

Airway and respiratory treatment always take priority.

Gastric Lavage

The older recommendation for routine gastric lavage after a significant ingestion is outdated.

Routine gastric lavage is not recommended.

Only an extraordinary:

• Immediately life-threatening
• Very recent

ingestion could justify considering lavage after:

• Airway protection
• Specialist toxicology consultation

Eye / Skin Exposure

For significant inadvertent topical exposure:

• Remove contaminated clothing
• Wash skin with soap and water

For inappropriate ocular exposure to a non-ophthalmic preparation:

• Irrigate with water/saline
• Evaluate persistent ocular symptoms

Therapeutic miotic eye drops themselves are not managed by simply “washing them out” once absorbed; treatment is symptom directed.

Succinylcholine – Important Distinction

Anticholinesterase poisoning can prolong succinylcholine paralysis because cholinesterase activity is inhibited.

However:

An isolated direct receptor agonist does not inhibit cholinesterase.

Therefore the blanket warning to avoid succinylcholine in every “cholinergic” drug poisoning does not automatically apply to a confirmed direct muscarinic agonist exposure.

If organophosphate/carbamate poisoning is possible, a nondepolarizing paralytic such as rocuronium remains preferable.

Enhanced Elimination

There is no established routine role for:

• Hemodialysis
• Hemoperfusion
• Urinary alkalinization
• Forced diuresis

for typical direct cholinergic agonist medication poisoning.

Pilocarpine labeling specifically states that whether it is dialyzable is unknown.

Supportive care and atropine are generally sufficient.

Monitoring

Symptomatic patients should have:

• Respiratory monitoring
• Pulse oximetry
• Frequent lung examinations
• Blood-pressure monitoring

Continuous ECG monitoring is appropriate with:

• Bradycardia
• Hypotension
• Syncope
• Significant systemic poisoning

Reassess:

• Secretions
• Wheezing
• Heart rate
• Blood pressure
• Mental status

after every atropine dose.

Observation

The old statement that toxicity routinely:

“peaks within 6–12 hours and may take days to recover”

is too broad for this diverse class.

Duration depends heavily on the agent.

For example:

• Acetylcholine has extremely brief activity
• Methacholine challenge effects are generally short and actively reversed
• Bethanechol commonly acts for several hours or less
• Oral pilocarpine/cevimeline can produce more sustained systemic effects
• Natural-product ingestion may have a different time course

Therefore:

Observation should be agent- and symptom-specific rather than a fixed 4–6-hour rule.

Admission

Hospital admission is appropriate for:

• Clinically important bronchospasm
• Persistent bronchial secretions
• Recurrent atropine requirement
• Significant bradycardia
• Hypotension
• AV block/dysrhythmia
• Hypoxemia
• Severe vomiting/diarrhea with dehydration
• Altered mental status
• Seizure

ICU-level care is appropriate for:

• Respiratory failure
• Intubation
• Severe bronchospasm
• Hemodynamic instability
• Recurrent serious dysrhythmia

Not every mildly symptomatic patient requires ICU admission, contrary to the older recommendation.

Discharge

Patients may be discharged when:

• Symptoms have fully resolved
• Oxygenation is normal
• No clinically important bronchospasm remains
• Heart rate/BP are stable
• No recurrent atropine is required
• Oral intake is tolerated when appropriate
• The expected duration of the specific agent has been considered

Intentional overdose also requires appropriate psychiatric/safety assessment.

Pregnancy

The historical FDA Pregnancy Category C system is obsolete.

Pregnancy safety data vary considerably between individual drugs.

For acute poisoning:

Maternal airway, oxygenation, and circulation take priority.

Atropine should not be withheld when needed to treat life-threatening muscarinic toxicity.

The potential maternal and fetal consequences of:

• Severe bronchospasm
• Hypoxia
• Bradycardia
• Hypotension

are more immediately dangerous than appropriate antidotal atropine therapy.

Prognosis

Most isolated direct cholinergic medication exposures have:

Good prognosis with prompt supportive care and atropine when required.

Severe morbidity is more likely when:

• Bronchospasm is not recognized
• Excess secretions compromise ventilation
• Profound bradycardia/hypotension develops
• Exposure is massive
• Coingestants are present

Direct agonist medication poisoning generally resolves faster than severe organophosphate poisoning because there is no persistent AChE phosphorylation or aging process.

Important Pitfalls

1. Treating all cholinergic poisonings as organophosphate poisoning

Direct agonists stimulate receptors.

Organophosphates inhibit AChE.

This fundamentally changes the role of pralidoxime.

2. Giving pralidoxime for confirmed bethanechol or pilocarpine overdose

There is no inhibited AChE enzyme for pralidoxime to reactivate.

Use atropine.

3. Checking cholinesterase levels to diagnose direct agonist toxicity

Cholinesterase levels are not expected to fall.

A normal level is therefore unsurprising.

4. Calling methacholine a major nicotinic agonist

Methacholine’s clinically important action is:

Muscarinic bronchoconstriction

Current Provocholine specifically warns about severe bronchospasm.

5. Missing severe methacholine bronchospasm

Treat rapidly with:

Inhaled β₂ agonist

rather than waiting for spontaneous recovery.

6. Assuming all direct cholinergic agents cause paralysis

Profound:

• Fasciculations
• Weakness
• Flaccid paralysis

are more suggestive of substantial nicotinic excess from anticholinesterase poisoning.

7. Using massive organophosphate atropine doses automatically

Direct muscarinic agonist overdose often responds to much smaller atropine doses.

Titrate to the patient.

8. Titrating atropine to pupil size

Treat:

• Bronchial secretions
• Bronchospasm
• Bradycardia/perfusion

not persistent miosis.

9. Forgetting atropine toxicity

Over-treatment can transform:

Cholinergic toxicity → anticholinergic delirium

especially because direct agonist poisoning is often relatively short-lived.

10. Assuming methacholine is a treatment for asthma

It does the opposite.

Methacholine is a:

Diagnostic bronchoprovocation agent

and current labeling carries a boxed warning for severe bronchoconstriction.

11. Using the old natural-product classification

Correct associations:

• Pilocarpus → pilocarpine
• Areca catechu nut → arecoline
• Inocybe/Clitocybe → muscarine

The betel leaf itself is not the primary source of arecoline.

12. Forgetting cevimeline

Cevimeline is an important modern direct muscarinic agonist used for:

Sjögren-associated xerostomia.

13. Missing new carbachol ophthalmic formulations

As of 2026, YUVEZZI (carbachol + brimonidine) is FDA-approved for adult presbyopia, expanding current therapeutic exposure beyond the older intraoperative preparations.

14. Using routine gastric lavage

Modern poisoning management does not support routine lavage for these pharmaceutical ingestions.

Supportive care and atropine matter far more.

High-Yield Toxicology Pearls

Direct cholinergic agonists = primarily muscarinic toxidrome

Think:

Wet + wheezy + slow

Typical syndrome:

Salivation + lacrimation + diaphoresis + diarrhea/vomiting + miosis + bronchospasm + bradycardia

Key points:

• Direct agonists bind cholinergic receptors directly
• They do not require acetylcholinesterase inhibition
• Important agents:
• Acetylcholine
• Bethanechol
• Carbachol
• Methacholine
• Pilocarpine
• Cevimeline
• Bethanechol → predominantly muscarinic
• Methacholine → predominantly muscarinic
• Pilocarpine → predominantly muscarinic
• Carbachol → muscarinic + nicotinic
• Arecoline → mainly muscarinic partial agonist with some nicotinic activity
• Major dangerous manifestations:
• Bronchospasm
• Bronchial secretions
• Bradycardia
• Hypotension
• Main antidote:
• ATROPINE
• Direct agonist overdose often needs much less atropine than severe OP poisoning
• Pilocarpine label example:
• Atropine 0.5–1 mg IV/SC, titrated
• Treat to:
• Controlled bronchial secretions
• Improved bronchospasm
• Adequate perfusion
• Do not titrate atropine to pupil size
• Pralidoxime is NOT indicated for confirmed isolated direct agonist poisoning
• Cholinesterase measurements are not clinically useful
• Severe methacholine bronchospasm:
• Rapid-acting inhaled β₂ agonist
• Methacholine challenge:
• Approved for airway-hyperreactivity testing in patients ≥5 years
• Contraindicated when baseline FEV₁ <60% predicted
• Pilocarpine:
• Used for xerostomia after head/neck radiation and Sjögren syndrome
• Cevimeline:
• Used for Sjögren-associated xerostomia
• Carbachol:
• Intraocular miotic
• 2026: carbachol/brimonidine YUVEZZI approved for presbyopia
• Natural sources:
• Areca nut → arecoline
• Inocybe/Clitocybe mushrooms → muscarine
• Pilocarpus → pilocarpine
• Do not induce vomiting
• Activated charcoal only for selected recent oral exposures with a protected airway
• Routine gastric lavage is obsolete
• No routine role for dialysis
• Most isolated direct-agonist poisonings recover completely with prompt supportive care and atropine

Toxicology – Chlorine

Core concept

Chlorine (Cl₂) is a highly reactive, water-soluble pulmonary irritant gas that primarily damages the eyes, upper airway, and lungs.

The classic exposure syndrome is:

Chlorine inhalation → immediate eye/throat burning + cough → bronchospasm/chest tightness → chemical pneumonitis ± noncardiogenic pulmonary edema/ARDS

The most important treatment is:

Remove from exposure + airway/oxygenation support + inhaled bronchodilators for bronchospasm

There is:

No specific antidote

Most mild exposures resolve completely, but significant exposures can cause progressive lung injury over several hours and occasionally persistent reactive airways dysfunction syndrome (RADS). Current CDC guidance notes that lung function usually returns toward baseline within about 7–14 days after uncomplicated exposure, although more serious exposures can produce prolonged respiratory problems.

Physical Properties

Chlorine is:

• Chemical formula: Cl₂
• Greenish-yellow gas at room temperature
• Pungent, highly irritating odor
• Approximately 2.5 times heavier than air
• Shipped industrially as a liquefied compressed gas
• Nonflammable, but a powerful oxidizing agent

It can accumulate in:

• Basements
• Pits
• Low-lying areas
• Poorly ventilated enclosed spaces

and may react dangerously with many combustible or reducing materials.

Important Terminology

Chlorine Gas ≠ Household Bleach

These are related but distinct exposures.

Chlorine gas

Cl₂

Primary toxicity:

Inhalational pulmonary injury

Household bleach

Usually contains:

Sodium hypochlorite (NaOCl)

Primary toxicity:

• Local irritation
• Caustic injury if concentrated
• Generation of toxic gases if mixed with other cleaners

Therefore, a patient who “drank chlorine” usually ingested hypochlorite solution, not gaseous molecular chlorine.

How Household Mixing Produces Toxic Gas

This is one of the most important practical chlorine toxicology points.

Bleach + Acid

For example:

• Toilet-bowl cleaner
• Hydrochloric-acid cleaner
• Vinegar

can produce:

CHLORINE GAS

Hypochlorite + acid → Cl₂ release

Bleach + Ammonia

Mixing hypochlorite bleach with ammonia-containing products produces:

CHLORAMINES

rather than simply molecular chlorine.

Chloramine gases are also respiratory irritants and can produce:

• Eye burning
• Cough
• Dyspnea
• Bronchospasm
• Pulmonary injury

Practical rule

Never mix bleach with another household cleaner.

Sources and Uses

Important exposure settings include:

• Water-treatment facilities
• Sewage treatment
• Swimming-pool maintenance
• Chemical manufacturing
• Pulp/paper and textile bleaching
• Plastics and synthetic-material production
• Cleaning accidents
• Industrial chlorine-cylinder leaks
• Accidental mixing of household cleaning agents

Chlorine has also historically been used as a chemical warfare agent.

Routes of Exposure

Inhalation

By far the most important route.

Eyes

Gas or liquid splashes can produce significant injury.

Skin

Concentrated chlorine gas, liquid chlorine, or chlorine-generating solutions can cause chemical injury.

Ingestion

Elemental chlorine is a gas at room temperature, so ingestion typically refers to:

Sodium/calcium hypochlorite solutions

rather than Cl₂ itself.

Toxic Dose / Concentration

Toxicity is determined by:

Concentration × duration of exposure

There is no single clinically reliable toxic dose.

Historical human observations suggest:

• Approximately 1–10 ppm can produce irritation
• Concentrations above roughly 15 ppm can cause significant respiratory distress
• Very high concentrations can produce rapidly fatal pulmonary injury

ATSDR historically estimated a lowest lethal concentration around 430 ppm for 30 minutes, but such numbers should not be interpreted as safe/unsafe cutoffs.

A far more useful occupational emergency threshold is:

NIOSH IDLH = 10 ppm

meaning 10 ppm is considered immediately dangerous to life or health.

Pathophysiology

Chlorine readily reacts with water present on moist respiratory surfaces.

A simplified reaction produces:

Cl₂ + H₂O → hydrochloric acid + hypochlorous acid

This initiates:

• Oxidative injury
• Chlorination reactions
• Free-radical formation
• Direct epithelial damage

The older concept that chlorine toxicity is simply due to formation of hydrochloric acid and hypochlorous acid is incomplete.

Modern understanding emphasizes:

Oxidative injury + epithelial disruption + inflammatory signaling

as major contributors to pulmonary damage.

Airway and Lung Injury

Chlorine causes:

Epithelial injury → increased permeability → inflammation → bronchoconstriction + alveolar-capillary leak

This can produce:

• Bronchospasm
• Airway edema
• Chemical pneumonitis
• Noncardiogenic pulmonary edema
• ARDS

The degree of water solubility means much of the gas is absorbed in the upper respiratory tract, but sufficiently high exposure reaches and injures distal bronchioles and alveoli.

Why Symptoms Can Worsen Later

Severe chlorine injury does not always peak immediately.

The sequence may be:

Exposure → irritation/cough → transient improvement → increasing dyspnea/hypoxemia → pulmonary edema

Pulmonary injury in symptomatic patients can progress for several hours after exposure.

Therefore:

A normal early chest radiograph does not exclude evolving serious lung injury.

Risk Factors for Severe Toxicity

Greater risk occurs with:

• High concentration
• Longer exposure
• Enclosed-space exposure
• Delayed escape
• Preexisting asthma
• COPD
• Other chronic pulmonary disease

Children may be especially vulnerable because:

• Smaller airway diameter
• Greater minute ventilation per kilogram
• Short stature may place them closer to heavier-than-air chlorine concentrations near ground level.

Clinical Features

Mild Exposure

Typical findings:

• Eye irritation
• Lacrimation
• Rhinorrhea
• Burning nose/throat
• Sore throat
• Cough
• Mild chest burning
• Headache

Symptoms usually begin rapidly.

Moderate Exposure

Possible findings:

• Persistent cough
• Chest tightness
• Dyspnea
• Wheezing
• Hoarseness
• Tachypnea
• Bronchospasm
• Hypoxemia

A patient may describe:

“Burning in the chest”

which is characteristic of significant irritant-gas exposure.

Severe Exposure

High-dose exposure can cause:

• Severe bronchospasm
• Upper-airway edema
• Stridor
• Hemoptysis
• Diffuse crackles
• Severe hypoxemia
• Noncardiogenic pulmonary edema
• ARDS
• Respiratory failure
• Cardiovascular collapse

Severe hypoxia can cause:

• Confusion
• Syncope
• Seizures
• Cardiac arrest

HEENT

Common findings include:

• Blepharospasm
• Conjunctival injection
• Tearing
• Nasal irritation
• Pharyngeal irritation

Severe exposure can cause:

• Corneal epithelial injury
• Corneal burns

Upper Airway

Warning findings include:

• Hoarseness
• Drooling
• Stridor
• Progressive respiratory distress
• Inability to manage secretions

Significant laryngeal edema can make later intubation difficult.

Therefore:

Progressive upper-airway obstruction → secure the airway early.

Pulmonary

Common respiratory findings include:

• Cough
• Wheezing
• Rhonchi
• Crackles
• Tachypnea

More severe toxicity:

• Hemoptysis
• Hypoxemia
• Pulmonary edema
• ARDS

Current systematic reviews find that the dominant clinical features of civilian chlorine exposures are cough and dyspnea; the majority recover completely, although severe exposures can be fatal.

Cardiovascular

Cardiac abnormalities are usually secondary to:

• Hypoxemia
• Severe pulmonary injury
• Physiologic stress

Possible findings:

• Tachycardia
• Initial hypertension
• Later hypotension
• Cardiovascular collapse in profound exposure

Chlorine does not characteristically cause a primary cardiotoxic dysrhythmia syndrome.

Neurologic

Mild:

• Headache
• Dizziness
• Lightheadedness

Severe:

• Confusion
• Syncope
• Seizures/coma secondary to major hypoxia

Marked altered consciousness should prompt consideration of:

• Severe hypoxemia
• Additional toxicant
• Trauma
• Alternative diagnosis

Acid–Base Effects

Massive inhalation can occasionally produce:

Hyperchloremic metabolic acidosis

although metabolic acidosis in critically ill patients may also reflect:

• Hypoxia
• Shock
• Lactate accumulation

Skin

Gas exposure usually causes mild irritation.

More concentrated exposure may cause:

• Burning
• Erythema
• Blistering
• Chemical burns

Liquefied chlorine

Contact with liquefied compressed chlorine can additionally produce:

Frostbite

because of rapid evaporative cooling.

Ocular Exposure

Possible findings:

• Immediate burning
• Tearing
• Blepharospasm
• Conjunctivitis

Severe exposure:

• Corneal epithelial injury
• Corneal burn

Persistent:

• Pain
• Photophobia
• Visual change

requires formal ophthalmologic evaluation.

Household Bleach Ingestion

Low-concentration household sodium hypochlorite exposures are generally much less dangerous than concentrated industrial hypochlorite.

Small accidental swallows commonly cause:

• Oral irritation
• Nausea
• Vomiting
• Abdominal discomfort

More concentrated products can cause:

True caustic injury

including:

• Odynophagia
• Dysphagia
• Esophagitis
• Gastric injury
• Hematemesis
• Perforation in extreme cases

Modern household products vary in concentration; some are more concentrated than the traditional 3–6% bleach formulations.

Diagnosis

Diagnosis of chlorine inhalation is primarily:

Clinical

based on:

• Exposure history
• Characteristic odor/event
• Immediate mucosal irritation
• Respiratory findings

There is no clinically useful:

• Serum chlorine concentration
• Urinary chlorine assay

for routine emergency diagnosis.

Differential Diagnosis

Other pulmonary irritant exposures include:

• Ammonia
• Bromine
• Phosgene
• Nitrogen dioxide
• Sulfur dioxide
• Acrolein
• Smoke inhalation
• Chloramine gases

Also consider:

• Asthma exacerbation
• Anaphylaxis
• Pneumonia
• Pulmonary edema
• Aspiration

In structure-fire patients, also consider:

• Carbon monoxide
• Cyanide
• Multiple combustion products

Investigations

Mild Exposure

No laboratory testing is usually needed when symptoms:

• Are minor
• Resolve quickly
• Have a reliable low-level exposure history

Respiratory Evaluation

For significant respiratory symptoms obtain:

• Continuous pulse oximetry
• Serial lung examination

Consider:

• Blood gas
• Chest radiograph

for:

• Persistent dyspnea
• Hypoxemia
• Severe cough
• Crackles
• Hemoptysis
• Significant exposure

Chest Radiograph

Possible abnormalities include:

• Diffuse infiltrates
• Pulmonary edema
• Patchy chemical pneumonitis

However:

An early normal CXR does not exclude later pulmonary edema.

Clinical observation remains important.

Laboratory Tests

Moderate/severe exposures may warrant:

• Electrolytes
• Bicarbonate
• BUN
• Creatinine
• Glucose

For critical illness:

• Blood gas
• Lactate

CBC may be obtained when:

• Serious pulmonary injury
• Infection differential
• Critical illness

is present.

Pulmonary Function

Peak expiratory flow or spirometry can be useful in patients with:

• Bronchospasm
• Persistent respiratory symptoms
• Suspected RADS

but is not required in every acute exposure.

Bronchoscopy

Routine bronchoscopy is not necessary.

It may be considered for:

• Severe airway injury
• Persistent unexplained respiratory failure
• Suspected inhalational mucosal injury
• Airway obstruction requiring direct assessment

Treatment

1. Rescuer Safety

Do not enter a high-concentration chlorine environment without appropriate respiratory protection.

For unknown or dangerous concentrations:

Positive-pressure self-contained breathing apparatus (SCBA) is required.

Because chlorine is heavier than air:

Move upwind and to higher ground when practical.

2. Remove From Exposure

The single most important immediate intervention is:

Fresh air

Move the patient rapidly away from the contaminated environment.

A patient exposed only to chlorine gas without contaminated clothing or liquid chemical generally does not remain a significant secondary contamination hazard once removed from the source.

3. Airway

Assess for:

• Hoarseness
• Stridor
• Progressive edema
• Severe respiratory distress
• Altered consciousness

If airway compromise is evolving:

Intubate early

Use direct visualization/video laryngoscopy or other controlled techniques.

Severe edema can make delayed airway management extremely difficult.

4. Oxygen

Give supplemental oxygen for:

• Dyspnea
• Hypoxemia
• Significant respiratory distress

Patients with severe toxicity may require:

• High-flow oxygen
• Noninvasive support in carefully selected cases
• Endotracheal intubation/mechanical ventilation

Current systematic evidence supports exposure cessation and oxygen as core supportive therapies.

5. Bronchospasm

Inhaled β₂ agonists are standard treatment.

Examples:

• Albuterol
• Salbutamol

Ipratropium may be added for severe bronchospasm according to standard obstructive-airway management.

Systematic review evidence supports inhaled bronchodilators as standard therapy for chlorine-associated bronchoconstriction.

6. Pulmonary Edema / ARDS

Treat according to standard supportive critical-care principles:

• Oxygen
• Appropriate PEEP
• Lung-protective ventilation
• Conservative fluid strategy once shock is corrected

Chlorine-induced pulmonary edema is generally:

Noncardiogenic

so routine diuretics are not an antidote and should not be automatically administered unless there is an independent indication.

7. Corticosteroids

Important modernization

The older text recommends prednisone or methylprednisolone rather broadly after chlorine inhalation.

Modern evidence does not support routine corticosteroids for every chlorine exposure.

Human studies are limited and confounded because steroids are usually administered together with:

• Oxygen
• Bronchodilators
• Other therapies

Systematic reviews conclude that the independent benefit of corticosteroids remains uncertain.

Reasonable use

Steroids may be considered when there is:

• Significant asthma/reactive-airway exacerbation
• Persistent bronchospasm consistent with usual asthma indications

But:

Routine prophylactic steroids to prevent pulmonary edema or fibrosis are not evidence-based.

Nebulized Sodium Bicarbonate

This requires correction from the older text.

The older chapter states that sodium bicarbonate is ineffective and may itself cause chemical pneumonitis.

Current evidence is more nuanced.

A randomized human study using nebulized bicarbonate in chlorine-induced RADS found modest improvement in FEV₁ at 2 and 4 hours, but no evidence that it prevents major outcomes such as:

• Intubation
• Pulmonary edema
• Long-term lung disease
• Mortality

Therefore:

Nebulized sodium bicarbonate is not established first-line therapy.

It may be considered as an adjunct in selected symptomatic patients after consultation with a poison center/medical toxicologist.

It should never replace:

• Fresh air
• Oxygen
• Bronchodilators
• Airway management

No Specific Antidote

There is no antidote for chlorine gas toxicity.

Current CDC and NIOSH guidance emphasizes supportive respiratory care.

Skin Decontamination

For liquid/chlorine-generating chemical contamination:

• Remove contaminated clothing
• Rinse exposed skin/hair with copious tepid water
• Wash with mild soap
• Rinse again

Patients exposed only to gas and without skin/eye irritation usually do not require full decontamination.

Liquefied Chlorine Frostbite

If liquefied chlorine causes frostbite:

• Do not rub
• Remove constricting items
• Rewarm in water approximately 40–42°C

until tissue perfusion returns.

Eye Decontamination

Immediately:

Irrigate with copious water or saline for at least 15 minutes

Remove contact lenses when easily possible.

Then assess:

• Visual acuity
• Cornea

Persistent:

• Pain
• Photophobia
• Vision change
• Corneal injury

requires urgent ophthalmology assessment.

Hypochlorite Ingestion

Do NOT induce vomiting

Never induce emesis.

This risks:

• Re-exposure of the esophagus
• Aspiration

CDC/ATSDR guidance specifically advises against induced vomiting.

Activated Charcoal

Do not routinely give activated charcoal for hypochlorite ingestion.

It provides little benefit and may:

• Promote vomiting
• Increase aspiration risk
• Complicate subsequent endoscopic assessment

Gastric Lavage / Aspiration

The older recommendation for nasogastric aspiration after a large ingestion is not modern routine practice.

Routine gastric lavage is not recommended.

Potential complications include:

• Perforation
• Aspiration
• Additional mucosal trauma

ATSDR specifically notes that gastric lavage is generally not recommended for hypochlorite ingestion.

Oral Dilution After Bleach Ingestion

Older guidance recommends 4–8 oz of milk or water.

Modern practice is more conservative.

After a small recent lower-concentration household bleach exposure, an alert patient who can swallow normally may rinse the mouth and take a small amount of water.

However:

Do not force oral dilution in a symptomatic patient or significant caustic ingestion.

Avoid oral fluids with:

• Drooling
• Dysphagia
• Repeated vomiting
• Airway compromise
• Severe pain
• Suspected perforation

The patient’s airway and GI injury assessment take priority.

Endoscopy After Hypochlorite Ingestion

Routine endoscopy is unnecessary after an uncomplicated small household bleach exposure.

Consider GI/endoscopic evaluation with:

• Concentrated product
• Intentional large ingestion
• Persistent vomiting
• Drooling
• Odynophagia/dysphagia
• Chest or abdominal pain
• Hematemesis
• Other evidence of caustic injury

Severe hypochlorite ingestion should be managed according to general caustic-ingestion principles.

Antibiotics

Routine prophylactic antibiotics have no established role after isolated chlorine inhalation.

Use antibiotics only when there is evidence of:

• Bacterial pneumonia
• Aspiration infection
• Another infectious process

Chemical pneumonitis alone is not an indication for antibiotics.

Monitoring

Symptomatic patients should be monitored for:

• Respiratory rate
• Oxygen saturation
• Work of breathing
• Bronchospasm
• Progression of chest symptoms

Continuous cardiac monitoring is reasonable in:

• Severe hypoxemia
• Critical illness
• Significant coexposures

Observation

The older concept of a rigid observation interval is less useful than clinical severity.

Minor exposure

Patients with only:

• Transient throat/eye irritation
• Minimal cough
• Normal oxygenation

who become fully asymptomatic may often be discharged after an appropriate period of observation.

ATSDR notes that minor symptoms commonly resolve within about an hour.

Significant exposure

Patients with:

• Persistent cough
• Dyspnea
• Chest tightness
• Wheezing
• Hypoxemia
• High-concentration exposure

should be observed longer because:

Pulmonary injury may progress over several hours.

Admission

Hospital admission is appropriate for:

• Persistent dyspnea
• Severe/persistent cough
• Significant bronchospasm
• Hypoxemia
• Hemoptysis
• Upper-airway edema
• Stridor
• Abnormal CXR with pulmonary injury
• Noncardiogenic pulmonary edema
• Significant ocular/skin burns
• Significant caustic hypochlorite ingestion

ICU care is appropriate for:

• Progressive hypoxemia
• Respiratory failure
• ARDS
• Mechanical ventilation
• Hemodynamic instability

Discharge

Discharge requires:

• Resolution or clear improvement of respiratory symptoms
• Normal/reassuring oxygenation
• No progressive airway findings
• Ability to ambulate without significant dyspnea
• Reliable return precautions

Patients should return urgently for:

• Increasing cough
• Wheezing
• Dyspnea
• Chest pain
• Hemoptysis

because deterioration can occur after apparent early improvement.

Long-Term Pulmonary Effects

Most patients recover completely.

Systematic civilian data reported full recovery in approximately 90% of cases with available follow-up.

However, significant exposure can produce:

Reactive Airways Dysfunction Syndrome (RADS)

which is irritant-induced asthma developing after a major exposure.

Symptoms may include:

• Persistent cough
• Wheezing
• Exercise intolerance
• Airway hyperreactivity

ATSDR reports that chlorine-induced RADS has occasionally persisted for years.

Pulmonary Fibrosis

Older sources often emphasize interstitial fibrosis as a common sequela.

Persistent structural lung disease can occur after severe exposure, but:

Permanent pulmonary fibrosis is not the expected outcome of most chlorine exposures.

Most patients recover substantially, while persistent airway hyperreactivity/RADS is a more clinically recognized long-term syndrome.

Pregnancy

The older claim that concentrated hypochlorite is clearly teratogenic should not be directly extrapolated to human chlorine-gas poisoning.

Available data are insufficient to establish a specific human teratogenic syndrome from chlorine exposure.

In significant maternal poisoning, the main fetal threats are likely secondary to:

• Maternal hypoxemia
• Respiratory failure
• Hemodynamic instability

Therefore:

Maternal airway and oxygenation are the priorities.

Do not withhold appropriate oxygen, bronchodilators, airway support, or critical care because of pregnancy.

Occupational Exposure Standards – Chlorine

The old workplace values are outdated.

Current NIOSH

REL: ceiling 0.5 ppm (1.45 mg/m³) over 15 minutes

Current OSHA

PEL: ceiling 1 ppm (3 mg/m³)

NIOSH IDLH

10 ppm

Important correction

The older chapter states:

• OSHA TWA 0.5 ppm
• OSHA STEL 1 ppm
• IDLH 25 ppm

Those values should not be used.

Current federal OSHA is a 1-ppm ceiling, while current NIOSH IDLH is 10 ppm.

Chlorine Dioxide Is a Different Chemical

Chlorine dioxide (ClO₂) is not interchangeable with chlorine gas.

Current occupational values:

• NIOSH REL TWA: 0.1 ppm
• NIOSH STEL: 0.3 ppm
• OSHA PEL TWA: 0.1 ppm
• NIOSH IDLH: 5 ppm

Chlorine Trifluoride Is Also Distinct

Chlorine trifluoride (ClF₃) is a highly reactive fluorinating agent with additional extreme chemical hazards.

Current values:

• NIOSH REL ceiling: 0.1 ppm
• OSHA PEL ceiling: 0.1 ppm
• NIOSH IDLH: 12 ppm

It should not be managed as simply another formulation of ordinary chlorine gas.

Important Pitfalls

1. Confusing chlorine gas with bleach

Bleach contains hypochlorite.

The most dangerous household inhalational exposures frequently occur when bleach reacts with another cleaner.

2. Saying bleach + ammonia produces ordinary chlorine

More precisely:

Bleach + ammonia → chloramines

whereas:

Bleach + acid → chlorine gas

3. Trusting an early normal chest radiograph

Pulmonary edema may develop later.

Normal early CXR ≠ safe after a significant exposure.

4. Sending home a persistently symptomatic patient

Persistent:

• Dyspnea
• Severe cough
• Chest tightness

warrants continued observation/admission because lung injury can progress for several hours.

5. Giving steroids routinely

Evidence for corticosteroids specifically preventing chlorine lung injury is weak.

Use primarily when there is a separate clinical indication such as significant reactive-airway/asthma physiology.

6. Calling nebulized bicarbonate useless

Evidence shows a possible modest short-term spirometric benefit, but not proven major outcome benefit.

Therefore:

Possible adjunct—not standard antidote.

7. Forgetting bronchodilators

Bronchospasm is common and:

Inhaled β₂ agonists are standard therapy.

8. Treating pulmonary edema automatically with diuretics

Chlorine pulmonary edema is typically:

Permeability/noncardiogenic edema

Treat primarily with respiratory support.

9. Giving charcoal after bleach ingestion

Activated charcoal is not recommended for hypochlorite ingestion.

10. Performing gastric lavage after concentrated bleach ingestion

Routine lavage is inappropriate and may worsen caustic injury.

11. Missing airway edema

Hoarseness and stridor after major exposure may precede severe airway compromise.

Intubate before edema makes intubation impossible.

12. Ignoring low-lying chlorine accumulation

Chlorine is approximately 2.5 times heavier than air.

Children and incapacitated individuals near floor level can receive greater exposure.

13. Assuming the patient contaminates the ED indefinitely

After gas-only exposure, patients generally pose little secondary contamination risk once removed to clean air.

Liquid chemical contamination is different and requires decontamination.

14. Using the old IDLH

Current:

NIOSH IDLH = 10 ppm

not 25 ppm.

High-Yield Toxicology Pearls

Chlorine = water-soluble pulmonary irritant gas

Think:

Bleach/industrial chlorine exposure → burning eyes/throat + cough + bronchospasm → delayed pulmonary edema in severe cases

Key points:

• Chlorine is:
• Greenish-yellow
• Pungent
• Heavier than air
• Main route of serious exposure: inhalation
• Mechanism:
• Reaction with water
• Hypochlorous/hydrochloric acid formation
• Oxidative epithelial injury
• Main targets:
• Eyes
• Upper airway
• Bronchi
• Lungs
• Household chemistry:
• Bleach + acid → chlorine gas
• Bleach + ammonia → chloramines
• Mild exposure:
• Eye/throat irritation
• Cough
• Moderate:
• Chest tightness
• Wheezing
• Bronchospasm
• Severe:
• Stridor
• Hemoptysis
• Hypoxemia
• Noncardiogenic pulmonary edema
• ARDS
• Symptoms may worsen for several hours
• Normal early CXR does not exclude serious injury
• Treatment:
• Fresh air
• Oxygen when symptomatic/hypoxemic
• Inhaled β₂ agonists for bronchospasm
• Early airway control if progressive edema
• Lung-protective ventilation for ARDS
• Routine corticosteroids are not proven
• Nebulized sodium bicarbonate:
• May modestly improve short-term FEV₁
• Not established first-line therapy
• Consider only as an adjunct
• No specific antidote
• Eye exposure:
• Immediate irrigation ≥15 min
• Liquid chlorine can cause frostbite
• Small household-bleach swallows usually cause GI irritation
• Concentrated hypochlorite can cause caustic esophagogastric injury
• Do not induce vomiting
• Do not give routine activated charcoal
• Routine gastric lavage is not recommended
• Significant bleach ingestion + dysphagia/hematemesis → evaluate as caustic ingestion
• Major long-term complication:
• RADS / irritant-induced asthma
• Occupational chlorine limits:
• NIOSH ceiling: 0.5 ppm / 15 min
• OSHA ceiling: 1 ppm
• NIOSH IDLH: 10 ppm
• Chlorine dioxide and chlorine trifluoride are distinct chemicals with separate exposure limits and hazards

Toxicology – Chloral Hydrate

Core concept

Chloral hydrate is an old sedative-hypnotic that is rapidly converted to the active CNS depressant trichloroethanol (TCE).

The characteristic severe overdose syndrome is:

CNS depression → respiratory depression/coma + myocardial depression + catecholamine-sensitive ventricular dysrhythmias

The distinctive toxicologic danger is the combination of:

Coma + refractory ventricular dysrhythmias

Severe poisoning may produce:

• Respiratory failure
• Hypotension
• Ventricular tachycardia
• Torsades de pointes
• Ventricular fibrillation
• Cardiac arrest

Treatment is primarily:

Airway/ventilatory support + continuous ECG monitoring + targeted treatment of dysrhythmias

There is no specific chemical antidote.

Current Status and Uses

Chloral hydrate was historically used for:

• Insomnia
• Sedation
• Pediatric procedural sedation
• Preanesthetic medication
• Alcohol withdrawal

Most of these uses have largely been replaced by medications with better:

• Pharmacokinetics
• Safety margins
• Reversibility

such as benzodiazepines and dexmedetomidine.

The former U.S. product Somnote is listed by FDA as a discontinued chloral hydrate product with no generic equivalent. (FDA Access Data⁠)

Chloral hydrate nevertheless remains in use in some countries and institutions, particularly for pediatric diagnostic/procedural sedation, and may also be encountered through compounded preparations. Contemporary pediatric literature still describes its procedural use internationally. (PubMed Central (PMC)⁠)

In the United States, chloral hydrate remains a:

Schedule IV controlled substance

because of abuse/dependence potential. (PubChem⁠)

Forms

Historically available formulations included:

• Oral solution/syrup
• Capsules/tablets
• Rectal preparations

Current availability varies significantly by country.

The older routine adult insomnia dose of 0.5–1 g is mainly of historical relevance rather than a preferred modern insomnia regimen.

Toxic Dose

There is no reliably safe numerical cutoff after overdose.

Significant toxicity can occur after relatively modest supratherapeutic doses, particularly with:

• Other CNS depressants
• Cardiovascular disease
• Young age
• Delayed airway management

Historical reports describe fatalities after approximately:

4–10 g

but survival has also occurred after much larger doses with aggressive critical care and extracorporeal treatment. (PubMed⁠)

Thus:

Clinical toxicity is more important than the reported dose.

Pathophysiology

Active Metabolite – Trichloroethanol

Chloral hydrate itself has an extremely short presence in the circulation and is rapidly converted, primarily through alcohol dehydrogenase, to:

Trichloroethanol (TCE)

TCE accounts for much of the:

• Sedation
• Hypnosis
• CNS depression

Chloral hydrate and TCE are believed to enhance inhibitory signaling involving:

GABA-A receptors

although their mechanism is less precisely characterized than that of modern benzodiazepines. (PubMed Central (PMC)⁠)

Metabolism

A simplified pathway is:

Chloral hydrate → trichloroethanol → glucuronide metabolites

and:

Chloral hydrate → trichloroacetic acid (TCA)

TCE is the major active metabolite.

At therapeutic exposure its half-life is approximately:

8–12 hours

but in overdose its elimination can be markedly prolonged, with reported half-lives extending toward 24–35 hours or longer. (PubMed Central (PMC)⁠)

Therefore:

Clinical depression may substantially outlast disappearance of the parent chloral hydrate.

Ethanol Interaction

The older description of a simple “disulfiram-like reaction” is incomplete.

The more clinically important interaction is:

Chloral hydrate + ethanol → enhanced and prolonged CNS depression

Human pharmacokinetic studies found that ethanol can increase and prolong plasma TCE concentrations, while TCE can inhibit ethanol metabolism. (ASCPT⁠)

Thus:

Alcohol + chloral hydrate is a particularly dangerous sedative combination.

This interaction contributed historically to chloral hydrate’s notorious use in drug-facilitated intoxication.

Cardiac Toxicity

Cardiotoxicity is one of the most distinctive features of severe chloral hydrate poisoning.

Effects include:

• Reduced myocardial contractility
• Increased cardiac automaticity
• Shortened refractory periods
• Sensitization of the myocardium to catecholamines

This catecholamine sensitization predisposes to:

Ventricular ectopy → VT → VF

especially when endogenous or administered catecholamines are high. (PubMed Central (PMC)⁠)

Clinical Features

Neurologic

Possible manifestations include:

• Dizziness
• Lightheadedness
• Ataxia
• Dysarthria
• Somnolence
• Confusion
• Depressed reflexes

Severe poisoning:

• Coma
• Respiratory depression
• Rare seizures

The dominant neurologic syndrome is generally:

Sedative-hypnotic CNS depression

Respiratory

Severe poisoning may cause:

Bradypnea → hypoventilation → hypercapnia → apnea

Additional complications include:

• Loss of airway reflexes
• Aspiration
• Hypoxic injury

Early intubation is appropriate for:

• Progressive CNS depression
• Inadequate ventilation
• Loss of airway protection
• Severe cardiovascular toxicity

Current pediatric toxicology guidance specifically emphasizes early intubation when CNS or cardiovascular toxicity is progressing. (Royal Children’s Hospital⁠)

Cardiovascular

Possible effects include:

• Sinus tachycardia
• Hypotension
• Myocardial depression
• Ventricular ectopy
• Bigeminy
• Supraventricular tachyarrhythmias
• Ventricular tachycardia
• Torsades de pointes
• Ventricular fibrillation

A case series reported transient bigeminy after an estimated 219 mg/kg ingestion and torsades/VF after a much larger ingestion. (PubMed⁠)

Cardiovascular toxicity can dominate the presentation even when ventilation is being supported.

Gastrointestinal

Chloral hydrate is directly irritating to the GI tract.

Possible symptoms:

• Nausea
• Vomiting
• Epigastric pain
• Esophageal discomfort
• Abdominal pain

Gastric mucosal irritation can be substantial after large ingestion.

HEENT

Reported findings include:

• Miosis
• Mucosal irritation
• Occasionally a characteristic pungent/pear-like odor on the breath

These findings are neither sensitive nor specific enough to establish the diagnosis.

Hypothermia

Like other sedative-hypnotic poisonings, severe intoxication may result in:

Hypothermia

particularly after prolonged coma or environmental exposure.

Diagnosis

Diagnosis is generally:

Exposure history + sedative toxidrome ± characteristic ventricular dysrhythmias

There is no routine rapidly available serum chloral hydrate concentration that guides emergency management.

Laboratory Investigations

For significant poisoning obtain:

• Bedside glucose
• Electrolytes
• Potassium
• Magnesium
• Calcium
• Bicarbonate
• BUN
• Creatinine

In severe toxicity consider:

• Blood gas
• Lactate
• Liver enzymes
• CK after prolonged coma/seizures

For intentional overdose obtain appropriate coingestant testing, including:

• Acetaminophen concentration
• Salicylate concentration

when relevant.

ECG

Every significant chloral hydrate overdose requires an ECG and continuous cardiac monitoring.

Look for:

• Ventricular ectopy
• Bigeminy
• QT abnormalities
• Ventricular tachycardia
• Torsades
• VF

Serious dysrhythmias may occur abruptly.

Trichloroethanol Levels

Specialized laboratories can measure:

• TCE
• Trichloroacetic acid
• Related metabolites

However:

These levels are generally not rapidly available and should not guide initial emergency treatment.

Treatment remains clinical.

Differential Diagnosis

Consider other causes of CNS depression including:

• Ethanol
• Benzodiazepines
• Barbiturates
• Opioids
• Meprobamate
• Carisoprodol
• Baclofen
• Other sedative-hypnotics

If prominent ventricular dysrhythmias are present, also consider:

• Tricyclic antidepressants
• Cocaine
• Sodium-channel blockers
• Chlorinated hydrocarbons
• Electrolyte abnormalities

Treatment

1. Airway and Ventilation

The cornerstone of therapy is:

Aggressive supportive airway management

Provide:

• Oxygen
• Ventilatory assistance as necessary
• Continuous pulse oximetry
• Capnography when available

Intubate early for:

• Progressive coma
• Hypoventilation
• Recurrent vomiting with impaired consciousness
• Cardiovascular deterioration

Do not wait for profound hypoxemia.

2. Continuous ECG Monitoring

Significant poisoning requires:

• Cardiac monitor
• Defibrillator immediately available
• Frequent blood-pressure measurement
• Serial electrolytes

Correct:

• Hypokalemia
• Hypomagnesemia
• Hypocalcemia

because electrolyte abnormalities can amplify ventricular dysrhythmia risk.

3. Ventricular Dysrhythmias – Key Toxicology Point

Chloral-hydrate dysrhythmias may be unusually resistant to routine antiarrhythmics because of:

Myocardial catecholamine sensitization

Historical and modern case literature repeatedly describes successful control with:

β-adrenergic blockade

particularly:

• Esmolol
• Propranolol

(PubMed⁠)

Esmolol

Esmolol is particularly attractive in severe poisoning because:

• Very short half-life
• Rapid titratability
• Can be quickly discontinued if hypotension worsens

Thus:

Refractory catecholamine-sensitive ventricular tachydysrhythmia → consider esmolol with toxicology/cardiology input.

This is not routine therapy for uncomplicated sinus tachycardia.

Torsades de Pointes

Treat according to standard principles:

• Immediate defibrillation if unstable/pulseless
• Correct potassium
• Correct magnesium

Give:

IV magnesium sulfate

for torsades, although case guidance notes that it may not completely suppress chloral-hydrate–driven dysrhythmia. (Royal Children’s Hospital⁠)

β-blockade may still be needed when catecholamine sensitization is driving recurrent ventricular arrhythmia.

Ventricular Tachycardia

For unstable VT:

• Immediate synchronized cardioversion when appropriate

For pulseless VT/VF:

• Defibrillate according to ACLS

Lidocaine has occasionally been successful, but response is inconsistent. (PubMed⁠)

Therefore:

Do not repeatedly cycle through standard antiarrhythmics while ignoring the characteristic catecholamine-sensitive mechanism.

Catecholamines – Important Pitfall

Because chloral hydrate sensitizes the myocardium to catecholamines:

Exogenous β-adrenergic stimulation can precipitate or worsen ventricular dysrhythmias.

Pediatric toxicology guidance therefore advises avoiding catecholamine inotropes when possible in chloral hydrate poisoning. (Royal Children’s Hospital⁠)

One reported severe poisoning switched norepinephrine to the predominantly α-adrenergic agent phenylephrine because of this concern. (PubMed Central (PMC)⁠)

Practical approach

For hypotension:

1. Optimize oxygenation/ventilation
2. Give cautious isotonic fluid if volume responsive
3. Correct dysrhythmias
4. Seek toxicology/critical-care input early

If a vasopressor is necessary, an α-predominant strategy such as phenylephrine may be considered when catecholamine-sensitive ventricular arrhythmias are present.

This is a specialized situation; profound shock requires individualized critical-care management.

4. Hypotension

Possible mechanisms include:

• Myocardial depression
• Dysrhythmia
• Vasodilation
• Sedative toxicity